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Abstract 
Background Opioid misuse is a growing public health issue in the United States and is 
particularly concerning among people living with HIV (PLWH). Though PLWH are at high 
risk for opioid misuse, little research is available to describe or quantify risk factors for 
their elevated risk. Describing the trends in opioid prescribing among PLWH and 
identifying characteristics of PLWH at highest risk for opioid misuse can help to guide the 
treatment of chronic pain while minimizing potential harms.  
 
Methods We examined trends in opioid and non-opioid oral analgesic prescribing among 
PLWH compared to individuals without HIV. Next, we identified factors associated with 
high-risk opioid use by analyzing prescription claims from individuals attending HIV clinics 
in the United States. Finally, we applied an indirect questioning technique to estimate the 
prevalence of opioid diversion in the absence of social desirability bias. 
 
Results We found an increasing trend in prevalence for both opioid and non-opioid 
analgesics between 2001-2009 regardless of HIV status. In all years, PLWH received more 
analgesic prescriptions compared to individuals without HIV. PLWH had a higher incidence 
of chronic opioid therapy (COT), defined as ≥90 consecutive days of opioid use, but the 
increased hazard for COT was explained by differences in co-morbidities. High-risk opioid 
use was common among PLWH, with approximately one third of PLWH who had received 
an opioid prescription meeting high-risk use criteria. Nearly half of all high-risk opioid use 
occurred within one year of receiving an opioid prescription. Using an indirect questioning 
technique, we found that 11.5% of patients at an urban HIV clinic had ever given away or 
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sold their opioid prescriptions. This prevalence of opioid diversion was twice as high as the 
prevalence obtained by directly asking patients if they had ever diverted opioids. 
 
Conclusion High rates of opioid prescribing and COT among PLWH are concerning because 
they may lead to opioid misuse; high-risk use patterns and opioid diversion were both 
common in our study. Applying our results to assess patients’ risk for opioid misuse and 
carefully monitoring prescribing patterns to avoid over-prescribing may help to mitigate 
adverse consequences of opioid misuse and reduce opioid diversion.  
  
 iv 
Readers and Advisors 
Committee Members: 
 
Bryan Lau, PhD (Advisor) 
Associate Professor 
Department of Epidemiology 
 
G. Caleb Alexander, MD 
Associate Professor 
Department of Epidemiology 
 
Geetanjali Chander, MD 
Associate Professor 
School of Medicine 
 
Carl Latkin, PhD 
Professor 





Becky Genberg, PhD 
Assistant Professor 
Department of Epidemiology 
 
Renee Johnson, PhD 
Associate Professor 




I am grateful for the dedicated and tireless work of so many people who helped me 
to complete this doctoral dissertation. First and foremost, I’d like to thank my advisor, 
Bryan Lau, for the guidance he provided over the past four years. He offered expert advice 
on the research process and the field of epidemiologic methods, constantly pushed me to 
produce the best work I could, and always reminded me to think about the big picture and 
implications of my research. I’ll never forget the valuable lessons he has taught me, and for 
that I thank him sincerely.  
 Next, I’d like to thank the other two members of my thesis committee, Caleb 
Alexander and Geetanjali Chander. They were instrumental in this work and always made 
time in their busy schedules to attend thesis committee meetings and provide feedback on 
my manuscripts. I value their perspectives and guidance tremendously and owe them both 
many thanks, not only for all the help they gave me on my dissertation, but also for each 
giving me the opportunity to work on interesting supplemental projects. 
Many thanks also to my other thesis readers and alternates, Carl Latkin, Becky 
Genberg, and Renee Johnson. Despite being busy researchers, they all agreed participate as 
thesis readers and I greatly value the time they’ve taken to read my work and help me 
improve my dissertation. I also thank the rest of the committee members and alternates for 
my departmental and preliminary oral exams, who were some of the first critics of my 
dissertation proposal: Lisa Jacobson, Mara McAdams DeMarco, Stephan Ehrhardt, David 
Dowdy, Elizabeth Stuart, and Elizabeth Colantouni.  
 Many people provided essential assistance throughout my dissertation. Their help 
was often behind-the-scenes but I could not have done any of this without them. Many 
 vi 
thanks to Keri Althoff and NA-ACCORD for providing me with the use of the Medicaid data 
and ACG® software, Aimee Freeman for helping with Medicaid data request, Gayle Springer 
and Yan Huang for helping me navigate the STATEPI server, Bin Liu for teaching me to use 
the ACG® software, Irene Murimi for advising me on the challenges and benefits of using 
pharmaceutical claims data for research, and the staff at ResDAC and CMS for their 
assistance with the Medicaid data. Many thanks also to the HIVRN collaborators, in 
particular Anne Monroe, Richard Moore, and Kelly Gebo, who provided instrumental 
guidance on the high-risk opioid use manuscript and encouraged me to present the work at 
SGIM. Finally, many thanks to Jeanne Keruly for helping to pull all the data for my opioid 
diversion paper and to Greg, Rob, and their colleagues at UW for programming (and re-
programming) the opioid diversion questions. 
I owe a sincere debt of gratitude to Shruti Mehta and Chris Beyrer for providing me 
with funding through T32 HIV Training Grant. The work they do is inspiring and I am 
grateful for the opportunity to have worked alongside them. Thank you also to Kristin Hunt 
for helping to facilitate all the details of the training program. 
 Fran Burman and Matt Miller are cornerstones to this program. They’re always 
quick to provide answers or simply reassurance. They know all the ins-and-outs of the 
program and never appear to tire of reciting the same line to every student who inevitably 
walks through their doors with the same questions, year after year. Their devotion to the 
students is unmatched. Thank you for looking out for us.  
Of course, none of this research would be possible without the participants in the 
HIVRN research studies, the patients at the Johns Hopkins HIV Clinic, and the Medicaid 
 vii 
enrollees whose claims I analyzed. Thank you to all individuals who participate in research 
studies and provide data to advance public health. 
My JHSPH colleagues, classmates and friends, particularly our weekly “writing 
accountability” group, made my experience at Hopkins brighter. I can’t possibly name 
everyone who deserves thanks for everything they’ve done over the past four years, but a 
special thank you goes to Gillian, Leslie, Sheriza, Marisa, Keri, Emily, Usama, Nicole, 
Norazlin, Sally, and Hae-Young. To everyone in our 2013 epidemiology cohort: you are all 
such talented people. Public health is lucky to have you and I couldn’t have asked for a 
better group of colleagues. 
Next, I give my most heartfelt thanks to my family. Andrew, thank you for being such 
an incredible support system, for listening every time I needed a sounding board or boost 
of confidence, and for working hard to keep me grounded. Mom and Dad, thanks for 
reliably being my number one supporters since day one, unconditionally. Lindsay, Matt, 
and Addison, thanks for understanding my relentless schedule and never failing to send 
adorable baby pictures when I needed them most. Thank you all for your patience. 
I can’t conclude without acknowledging the Daily Grind, my constant companion 
throughout this process, as well as countless other coffee shops at which I’ve overstayed 




Table of Contents 
Abstract .................................................................................................................................................... ii 
Readers and Advisors ......................................................................................................................... iv 
Acknowledgements ............................................................................................................................... v 
Table of Contents ................................................................................................................................ viii 
List of Tables ......................................................................................................................................... xii 
List of Figures ...................................................................................................................................... xiii 
List of Supplementary Tables ........................................................................................................ xiv 
Chapter 1: Introduction ...................................................................................................................... 1 
Background ......................................................................................................................................................... 1 
Pharmaceutical pain treatment............................................................................................................................... 1 
Chronic pain and opioid treatment among PLWH .......................................................................................... 2 
Opioid diversion ............................................................................................................................................................ 4 
Indirect questioning methods .................................................................................................................................. 5 
Gaps in Knowledge ........................................................................................................................................... 6 
Conceptual Framework .................................................................................................................................. 8 
Specific Aims ....................................................................................................................................................... 9 
Overall Approach ........................................................................................................................................... 11 
References ........................................................................................................................................................ 12 
Chapter 2: Trends in opioid and non-opioid prescription oral analgesics by HIV 
status ....................................................................................................................................................... 16 
Abstract ............................................................................................................................................................. 16 
 ix 
Introduction ..................................................................................................................................................... 18 
Methods ............................................................................................................................................................. 19 
Study sample ................................................................................................................................................................. 19 
Statistical methods ..................................................................................................................................................... 22 
Results ............................................................................................................................................................... 24 
Prevalence of opioid and non-opioid analgesics ............................................................................................ 25 
Proportion of days covered .................................................................................................................................... 26 
Proportion of days covered: stratified ............................................................................................................... 27 
Incident chronic opioid therapy ........................................................................................................................... 29 
Discussion ......................................................................................................................................................... 30 
References ........................................................................................................................................................ 37 
Chapter 3: High-risk opioid use among people living with HIV .......................................... 62 
Abstract ............................................................................................................................................................. 62 
Introduction ..................................................................................................................................................... 64 
Methods ............................................................................................................................................................. 65 
Study sample ................................................................................................................................................................. 65 
Exclusion criteria and description of final sample ........................................................................................ 66 
High-risk opioid use ................................................................................................................................................... 67 
Explanatory variables ............................................................................................................................................... 68 
Statistical methods ..................................................................................................................................................... 70 
Results ............................................................................................................................................................... 72 
Incidence of high-risk use ........................................................................................................................................ 73 
Time-to-event analysis ............................................................................................................................................. 74 
Recurrence of early refills: a sensitivity analysis .......................................................................................... 75 
Overlapping prescriptions: a sensitivity analysis .......................................................................................... 76 
 x 
Association with emergency department visits ............................................................................................. 77 
Discussion ......................................................................................................................................................... 77 
HIV Research Network Site Acknowledgements ................................................................................ 83 
References ........................................................................................................................................................ 84 
Chapter 4: Estimating the prevalence of opioid diversion using an indirect 
questioning technique ....................................................................................................................... 99 
Abstract ............................................................................................................................................................. 99 
Introduction ................................................................................................................................................... 101 
Methods ........................................................................................................................................................... 102 
Statistical Methods .................................................................................................................................................. 104 
Results ............................................................................................................................................................. 106 
Prevalence of opioid diversion ........................................................................................................................... 107 
Secondary analyses ................................................................................................................................................. 107 
Discussion ....................................................................................................................................................... 108 
References ...................................................................................................................................................... 113 
Appendix: Sample size considerations ................................................................................................ 122 
Discussion ........................................................................................................................................... 123 
Summary of findings ................................................................................................................................... 123 
Implications and public health significance ...................................................................................... 125 
Limitations and strengths ......................................................................................................................... 129 
Defining opioid and non-opioid analgesics ................................................................................................... 129 
Time period of data ................................................................................................................................................. 129 
Challenges with primary data collection ........................................................................................................ 131 
Innovation and contribution to the literature.............................................................................................. 131 
 xi 
Future directions ......................................................................................................................................... 133 
Update analyses using data from recent years ............................................................................................ 133 
Validate and compare each high-risk prescribing behavior .................................................................. 134 
Continue research on opioid diversion ........................................................................................................... 134 
References ...................................................................................................................................................... 136 




List of Tables 
Table 1: Baseline demographic characteristics ........................................................................................................ 40 
Table 2: Number and proportion of individuals with at least one prescription opioid analgesic in 
each year, among full sample and diabetic subset, weighted ................................................................... 41 
Table 3: Number and proportion of individuals with at least one prescription non-opioid analgesic 
in each year, among full sample and diabetic subset, weighted .............................................................. 41 
Table 4: Number and proportion of individuals with at least one prescription opioid analgesic in 
each year, by age at baseline, weighted ............................................................................................................. 42 
Table 5: Number and proportion of individuals with at least one prescription opioid analgesic in 
each year, by sex, weighted ..................................................................................................................................... 42 
Table 6: Number and proportion of individuals with at least one prescription opioid analgesic in 
each year, by state, weighted ................................................................................................................................. 43 
Table 7: Development of chronic opioid therapy among opioid-naïve individuals ................................... 45 
Table 8: Development of chronic opioid therapy among opioid-naïve diabetics ....................................... 46 
Table 9: Descriptive statistics........................................................................................................................................... 88 
Table 10: Summary statistics for each high-risk use behavior ........................................................................... 89 
Table 11: Incidence rate of subsequent high-risk opioid use patterns among patients who met 
multiple criteria for high-risk use, by first-occurring high-risk use pattern ...................................... 90 
Table 12: Multivariable adjusted Cox regression model for time to first high-risk opioid use 
behavior .......................................................................................................................................................................... 91 
Table 13: Characteristics of study sample ............................................................................................................... 115 
Table 14: Stratified prevalence estimates for opioid diversion by hypothesized risk factors ........... 117 
Table 15: Results from multivariate logistic regression models using crosswise technique ............. 119 
  
 xiii 
List of Figures 
Figure 1: Conceptual Framework ..................................................................................................................................... 8 
Figure 2: Opioid Analgesic Prescriptions per 100 People .................................................................................... 47 
Figure 3: Non-Opioid Analgesic Prescriptions per 100 People .......................................................................... 48 
Figure 4: Proportion of Days Covered by an Opioid Analgesic, weighted ..................................................... 49 
Figure 5: Proportion of Days Covered by a Non-Opioid Analgesic, weighted .............................................. 50 
Figure 6: Proportion of Days Covered by an Opioid Analgesic, by age at baseline, weighted ............... 51 
Figure 7: Proportion of Days Covered by an Opioid Analgesic, by sex, weighted....................................... 52 
Figure 8: Proportion of Days Covered by an Opioid Analgesic, by state, weighted ................................... 53 
Figure 9: Kaplan-Meier estimate for the incidence of chronic opioid therapy, weighted ....................... 54 
Figure 10: Kaplan-Meier estimate for the incidence of chronic opioid therapy among diabetics, 
weighted ......................................................................................................................................................................... 55 
Figure 11: Flow diagram .................................................................................................................................................... 92 
Figure 12: Venn diagram .................................................................................................................................................... 93 
Figure 13: Cumulative incidence of high-risk opioid use ..................................................................................... 94 




List of Supplementary Tables 
Supplementary Table 1: Summary of pre-defined NDCs used to identify opioid and non-opioid 
analgesics ....................................................................................................................................................................... 56 
Supplementary Table 2: Source Population by State ............................................................................................. 59 
Supplementary Table 3: Eligible Sample by State.................................................................................................... 60 
Supplementary Table 4: Drug categories for non-opioid analgesics ............................................................... 61 
Supplementary Table 5: Summary of pre-defined NDCs used to identify opioid analgesics ................. 96 
Supplementary Table 6: Exploration of two types of Medicaid plans ............................................................. 97 
Supplementary Table 7: Exposure definitions .......................................................................................................... 98 
Supplementary Table 8: Summary of responses to opioid diversion questions ...................................... 120 
Supplementary Table 9: Estimated proportion of ‘yes’ responses to opioid diversion using 




Chapter 1: Introduction 
 
Background 
Chronic pain represents a serious healthcare burden in the United States, leading to 
a movement to measure pain as the fifth vital sign in many medical facilities1. This practice 
began informally in the mid-1990s and was officially adopted by the Joint Commission on 
Accreditation of Healthcare Organizations in 19992. A variety of treatments for pain exist, 
including physical therapy, psychological approaches such as meditation or cognitive 
behavioral therapy, and pharmaceuticals3. Pharmaceutical pain medication serves as a 
widely used treatment for pain and is the subject of much research and debate due to the 
increasing occurrence of misuse of the drugs4–6. The experience of pain and associated 
treatment options are of particular concern among people living with HIV (PLWH), as this 
population has a higher prevalence of risk factors both for developing pain and for 
misusing prescription pain medications. 
Pharmaceutical pain treatment 
Pharmaceuticals have become a common treatment for patients with pain, with over 
200 million claims for opioid analgesics being dispensed in the United States in 20007. 
Analgesics, the broad class of drugs used to treat pain, include non-steroidal anti-
inflammatory drugs (NSAIDs), acetaminophen, anticonvulsants, NMDA agonists, and 
opioids8. While all analgesics cause side effects, opioids are particularly dangerous because 
of their addictive nature. In addition to more general side effects such as sedation, 
dizziness, nausea, vomiting, and constipation, opioids can cause physical dependence, 
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tolerance, and addiction9. Because of the ability of opioids to cause dependency, 
controversy exists as to whether they should be used for the treatment of long-term 
chronic pain9, and medical providers must use caution when prescribing the drugs to 
patients with a tendency towards misuse. 
Despite the controversy, rates of opioid prescribing have increased dramatically 
over the past two decades. The number of opioid prescriptions dispensed in the United 
States increased annually since the turn of the century, reaching a peak of 81.3 
prescriptions per 100 Americans in 201210. Prescribing guidelines that focus on reducing 
inappropriate opioid prescribing and the development of interventions such as 
prescription drug monitoring programs have helped to halt the increase in opioid 
dispensing, leading to a slight decline in opioid prescribing since 201311. Nonetheless, we 
are still in the midst of a serious opioid epidemic as deaths from overdose and the 
prevalence of opioid misuse continue to rise12. 
As of 2011, drug poisonings surpassed motor vehicle accidents as the leading cause 
of injury death in the United States, with a majority of the poisonings attributed to 
opioids13. Approximately half of opioid overdose deaths involve a prescription opioid, with 
more than 15,000 deaths involving a prescription opioid in 201514. Another 2 million 
Americans suffer from substance use disorders related to prescription opioids15. With 
appropriate interventions, the morbidity and mortality associated with prescription opioid 
use can be prevented. 
Chronic pain and opioid treatment among PLWH 
Among PLWH, chronic pain is highly prevalent, with a prevalence estimates ranging 
from 25% to 80% among PLWH16 and estimates ranging from 61% to 80% among 
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individuals with AIDS17. Common types of pain reported among PLWH include HIV-related 
headaches, peripheral neuropathy, and back pain18. The increased pain experienced by 
PLWH compared to HIV-uninfected individuals is also due in part to HIV-associated 
neuropathy and ART-toxic neuropathy19. Improvements to combination antiretroviral 
therapy have led to a decreasing prevalence of symptomatic peripheral neuropathy20, but 
reports of increased levels of pain among PLWH still persist21. Pain often co-exists 
depressive symptoms and anxiety; higher rates of mental health co-morbidities among 
PLWH may contribute to their continued increase in chronic pain compared to the general 
population21. 
The use of opioids to ameliorate pain has been a controversial topic for all patients, 
and is particularly controversial among populations with a history of drug abuse. PLWH 
have a higher prevalence of both substance abuse and mental health disorders compared to 
the general population, both of which are risk factors of opioid misuse; as such, PLWH are 
at high-risk for developing aberrant opioid use19. This poses a challenge to clinicians 
treating pain among PLWH, as there must be a careful balance between treating symptoms 
and instigating a tendency towards drug abuse.  
Likely because of the high-risk characteristics exhibited by PLWH, there have been 
reports of under-treatment of pain among PLWH since 199722–24. Differences in the 
prevalence of pain by HIV status make it difficult to assess this claim, but research suggests 
that PLWH may in fact receive more opioid prescriptions compared to the general 
population25,26. Additionally, opioid misuse is more common among PLWH compared to 
individuals without HIV21,27, indicating that appropriate prescribing and careful monitoring 
of opioid therapy is especially important in this population. 
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Opioid diversion  
Consequences of opioid misuse not only lead to abuse and dependence, but also 
diversion, which is the unlawful transfer of prescribed opioids. Opioid diversion is 
particularly dangerous, as it results in unmonitored consumption of the drugs. The 
National Survey on Drug Use and Health found that over 70% of individuals who abuse 
prescription painkillers received the drugs through diversion28. Despite the high 
prevalence and severe negative consequences of opioid diversion, efforts to combat 
diversion in the United States are inconsistent and largely ineffective28, leading to a 
continued problem with opioid diversion across the country. 
Data on the prevalence of opioid diversion are very limited, due in part to challenges 
associated with measuring sensitive behaviors: individuals are hesitant to self-report 
behaviors such as opioid overuse or diversion that are stigmatized or illegal. The few 
studies that have examined opioid diversion have been primarily in high-risk European 
populations and have estimated the prevalence of opioid diversion between 10-34% 
among patients in opioid substitution treatment programs29,30. Though we are not aware of 
a study designed to estimate the prevalence of opioid diversion among PLWH specifically, 
two studies that examined the use of street methadone and buprenorphine among injection 
drug users in Baltimore, MD found no association between HIV status and the prevalence of 
street methadone or buprenorphine use31,32. Further research is needed to quantify the 
prevalence of opioid diversion among PLWH, as this estimate is currently unknown. 
An indirect method for estimating the prevalence of opioid misuse may provide a 
more accurate measurement and can be used to validate direct estimation methods. With 
an indirect questioning method, researchers induce a known amount of measurement 
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error into the study design, which provides anonymity to the respondent and increases the 
likelihood of honest responses. Under the assumptions that the induced measurement 
error is known and that the respondents understood the questioning method and 
answered correctly, researchers can obtain accurate estimates for the prevalence of the 
sensitive behavior by adjusting for the induced measurement error. 
Indirect questioning methods 
Indirect questioning methods were first introduced in 1965 when Warner published 
a paper on randomized response to eliminate “evasive answer bias”33. Under the Warner 
method, a respondent is presented with a spinner with two true/false questions, where 
question A is the complement to question B. The respondent spins the spinner, unobserved 
by the interviewer, and answers the question to which the spinner points. This method 
elicits more honest responses than direct questioning because the interviewer does not 
know which question the respondent is answering. However, drawbacks include the 
necessity for all respondents to answer a sensitive question and the infeasibility of a non 
face-to-face questionnaire because of the need for a randomization device. 
To avoid requiring all respondents to answer a sensitive question, the unrelated 
question model, developed in 1967, randomly assigns respondents to answer either the 
sensitive question or an unrelated question34. Similarly, under the forced choice 
randomized response technique developed in 1971, respondents are randomized to 
answer either “yes”, “no”, or the truth35. However, these modifications to Warner’s 
randomized response technique include a self-protective “no” answer that may reduce the 
accuracy of responses and, like the Warner method, require a randomization device. 
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As an alternative to the randomized response techniques, the item count technique, 
or unmatched count technique36, presents two groups of respondents each with a list of 
true/false questions and asks the respondents to report the number of true responses in 
the list. One list contains the sensitive question of interest; the second list does not. Under 
the assumption that the prevalence of the sensitive question is the same between the two 
groups, the difference in the number of true responses between the two groups provides an 
estimate for the prevalence of the sensitive question. The item count technique does not 
have a self-protective “no” answer and can be completed using mail-in questionnaire; 
however, prevalence estimates under this method have a large variance, requiring a large 
sample size for precision. 
More recently, the crosswise method was developed by Yu et al.37 as another non-
randomized response method for indirect questioning. Under this method, respondents 
simultaneously answer two true/false questions (one sensitive question and one non-
sensitive question) by stating whether the answer to both questions is the same or 
different. Because the respondent does not state whether the responses are true or false, 
the stigma associated with answering the sensitive question decreases and the respondent 
is more likely to provide an honest answer. In empirical testing, the crosswise method was 
shown to reduce under-reporting due to social desirability bias as compared to direct 
questioning38; however, few applications of this method exist in the literature.  
Gaps in Knowledge 
Trends in oral analgesic prescriptions have been examined in the general 
population and have shown an increase in opioid prescriptions, but not non-opioid 
analgesic prescriptions, over the past decade39. However, similar research has not been 
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conducted specifically within an HIV-infected population. Because PLWH are at a high risk 
for opioid misuse, prescribing patterns may differ between HIV-infected and uninfected 
individuals despite similar symptoms and reports of pain. Examining trends in the receipt 
of oral analgesics can help describe the setting in which PLWH are being treated for pain 
and can provide evidence for the presence or absence of differential pain treatment among 
patients by HIV status. Identifying and quantifying differential treatment patterns can help 
to guide appropriate treatment recommendations for managing pain in PLWH. 
There is a small body of literature describing predictors of aberrant opioid use 
among PLWH19,21,40,27, however, these studies have been cross-sectional in nature and were 
unable to describe the time from initiation of opioid therapy to the development of opioid 
misuse. Further research that describes predictors of high-risk use among PLWH and 
characteristics associated with a faster progression to high-risk use can be used to better 
target resources to prevent or mitigate opioid misuse. Supplementing the current body of 
literature on predictors of high-risk opioid use can also guide future studies into examining 
causal relationships between modifiable risk factors and high-risk opioid use, with the 
ultimate goal of reducing opioid-related morbidity and mortality. 
Assessing risk factors or predictors for opioid diversion has proven challenging. 
Clinical cohort studies face difficulties in assessing opioid diversion, as self-report is 
associated with questionable reliability and toxicology screens can be costly. Studies that 
use prescription claims to identify opioid misuse cannot identify diversion, as claims do not 
indicate whether the individual to whom the drug was prescribed has taken it as intended. 
Improved methodological techniques to better estimate the prevalence and risk factors for 
opioid diversion can help to describe the scope of the opioid diversion problem and may 
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aid in developing recommendations for appropriate prescribing behaviors. Because a 
majority of opioid misuse occurs among patients who received the drugs illegally, directly 
targeting opioid diversion as a key element of the opioid epidemic that requires 
intervention can have a huge impact on reducing the burden of the problem. 
Conceptual Framework 
The framework depicted in Figure 1 describes the conceptual model underlying this 
research. In this framework, we describe the associations we hypothesize exist between 
receiving an opioid analgesic prescription and developing high-risk opioid use.  
       Figure 1: Conceptual Framework 
 
We expect that having HIV-infection will lead to a decrease in oral analgesic 
prescriptions, despite a similar or increased level of pain reported by the individuals. 
Further, we hypothesize that age, sex, race, presence of psychiatric illness, and history of 
illicit substance use will be associated with both the prescription of an oral analgesic and 
the development of high-risk use. Additionally, we expect that the patterns of prescription 
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drug use will change over time, as indicated by the calendar year box that suggests a 
modification of the exposure-outcome by time. Finally, we believe similar demographic, 
clinical, and behavioral characteristics that are related to high-risk opioid use will be 
associated with self-reported opioid diversion, which is also impacted by stigma, social 
desirability, fear, and trust. 
Specific Aims 
PLWH are at an increased risk for pain, both due to HIV-associated neuropathy and 
to ART-toxic neuropathy. Treatment for such pain commonly involves the use of 
prescription pharmaceuticals, including opioid analgesics. Because PLWH engage in high-
risk behaviors at a higher rate than their uninfected counterparts, they are also at 
increased risk for misusing opioid prescriptions and consequently may receive opioid 
prescriptions less readily than lower-risk individuals. This research aims to compare 
trends in analgesic use among PLWH and individuals without HIV, to determine risk factors 
associated with high-risk opioid use among PLWH, and to estimate the prevalence of opioid 
diversion among PLWH in Baltimore, MD. 
 
Aim 1: To compare trends in the receipt of opioid and non-opioid analgesics among 
PLWH versus HIV-uninfected individuals over time and to estimate the incidence of 
progression to chronic opioid therapy among opioid-naïve PLWH. 
Several studies have reported an under-treatment of pain among PLWH. Therefore, we aim 
to compare the prescribing patterns of oral analgesics between PLWH and HIV-uninfected 
individuals and to determine whether PLWH have a higher incidence of progression to 
chronic opioid use. 
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Hypothesis 1: The increase in the prevalence of opioid prescriptions over time will be 
greater among HIV-uninfected individuals compared to PLWH.  
Hypothesis 2: PLWH will have a higher incidence of progression to chronic opioid therapy 
compared to individuals without HIV. 
 
Aim 2: To identify risk factors for high-risk opioid use and time to high-risk use 
among PLWH who receive a prescription for opioids. 
Among HIV-uninfected individuals, psychiatric illness and a history of substance abuse 
have been found to predict opioid misuse, but this association has not been replicated 
among PLWH.  
Hypothesis: PLWH with a diagnosis of psychiatric illness and with a history of drug abuse 
will have an increased prevalence of high-risk opioid use and will have a shorter time to 
high-risk use compared to individuals without these diagnoses. 
 
Aim 3: To describe the prevalence of opioid diversion among PLWH as determined 
by indirect questioning and to characterize risk factors for diversion.  
Accurately measuring the prevalence of opioid misuse presents challenges, as individuals 
are often hesitant to respond accurately to sensitive questions. Indirect questioning 
techniques can help to overcome this challenge and can enable the evaluation of factors 
associated with opioid diversion.  
Hypothesis: The calculated prevalence of opioid diversion will be higher using indirect 
questioning compared to the prevalence calculated using direct questioning.  
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Overall Approach 
The goals of this dissertation are to identify trends in the receipt of opioid and non-
opioid analgesics over time by HIV status, to estimate the incidence of high-risk opioid use 
patterns, and to determine characteristics associated with PLWH who exhibit high-risk use 
behavior, including opioid diversion. The study populations include: 1) United States 
Medicaid enrollees, whose claims files contain medical and pharmaceutical data from all 
billable healthcare encounters, 2) the HIV Research Network, a national multisite 
longitudinal research study composed of 18 sites across the United States and 3) the Johns 
Hopkins HIV Clinical Cohort (JHHCC), a prospective cohort assembled in 1989 that follows 
HIV infected individuals in Baltimore, MD from the onset of clinical care at the HIV clinic to 
death or loss to follow up. The three studies conducted as part of this research help to fill 
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Chapter 2: Trends in opioid and non-opioid prescription oral 




Background.  People living with HIV (PLWH) experience a higher prevalence of pain 
compared to their HIV-uninfected counterparts. Detailed, nationwide trends in the use of 
opioid and non-opioid analgesics among PLWH compared to individuals without HIV and 
the incidence of progression to chronic opioid therapy (COT) by HIV status are not well 
described. 
 
Methods. We analyzed Medicaid pharmaceutical claims from adults age 18-65 from 14 US 
states between 2001-2009 to identify rates of opioid and non-opioid analgesic 
prescriptions over time. We compared trends in prescribing rates by HIV status. Then, to 
reduce heterogeneity between PLWH and people without HIV, we 1) standardized the 
study sample to the characteristics of PLWH using inverse probability weights and 2) 
restricted the sample to a select subgroup of patients who shared a common comorbidity. 
The subgroup was defined by the presence of a diabetes diagnosis, chosen because of its 
relatively high prevalence and association with chronic pain. We estimated the incidence of 
COT among opioid-naïve individuals and estimated the association between HIV status and 
progression to chronic opioid use. 
 
Results. Rates of both opioid and non-opioid analgesic prescriptions increased between 
2001-2009. PLWH received approximately twice the number of analgesic prescriptions 
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compared to individuals without HIV. COT was more common among PLWH, with an 
incidence rate of 29.1 per 1,000 person-years (PY) compared to 9.3 per 1,000 PY among 
individuals without HIV. In an unadjusted Cox proportional hazards model, PLWH had 3.06 
(95% CI 2.76-3.39) times the hazard of COT compared to individuals without HIV. When 
applying inverse probability of HIV weights and restricting the sample to patients with 
diabetes, the rates of all analgesic prescriptions were approximately equal by HIV status 
and the unadjusted hazard ratio for COT decreased to 1.46 (95% CI 1.31-1.63). After 
adjusting the Cox proportional hazards model for age, sex, state of residence, comorbidity 
score, depression, bipolar disorder, and schizophrenia, the increased hazard for COT in the 
weighted subsample decreased to 1.26 (95% CI 0.97-1.63). 
 
Conclusions. Between 2001-2009, PLWH received more analgesic prescriptions compared 
to individuals without HIV, yet these differences appear to be primarily due to differences 
in demographics and co-morbidities. Nevertheless, the rate of COT is relatively high; HIV 
providers must be vigilant when prescribing analgesia to PLWH.  
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Introduction 
Chronic pain is highly prevalent among people living with HIV (PLWH), with 
prevalence estimates ranging from 25% to 80% among PLWH1 and estimates ranging from 
61% to 80% among individuals with AIDS2. In addition to common types of pain, including 
headaches, peripheral neuropathy, and back pain3, PLWH also experience HIV-associated 
neuropathy and ART-toxic neuropathy4. The development of improved combination 
antiretroviral therapy has led to a decreasing prevalence of symptomatic peripheral 
neuropathy5, but HIV-infected individuals continue to report an increased level of pain 
compared to their uninfected counterparts6. Because pain is a complex multidimensional 
construct influenced by both physiological and psychological factors, high rates of 
psychological symptoms among PLWH may contribute to their higher prevalence of pain6. 
In the era of heightened concern over opioid misuse7–10, treatment for chronic pain 
has become a great challenge. Because of the ability of opioids to cause dependency, 
controversy exists as to whether they should be used for the treatment of long-term 
chronic pain7; nonetheless, pharmaceuticals have become a common treatment for pain, 
with over 200 million claims for opioid analgesics being dispensed in the United States in 
200011. Reducing the number of opioid prescriptions in circulation and ensuring 
appropriate prescribing may help to minimize the consequences of the drug, particularly 
among populations at high risk for drug abuse.  
PLWH are an especially vulnerable population with respect to opioid use. Not only 
do they experience a higher prevalence of pain, but they also have a high prevalence of 
drug abuse and psychological co-morbidities compared to the general population and are 
considered at high-risk for developing aberrant opioid use4. Likely because of the high risk 
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characteristics exhibited by PLWH, there have been reports of under-treatment of pain 
among individuals living with HIV since 199712–14.  Nonetheless, recent studies have found 
an increased prevalence of opioid prescribing among PLWH compared to the general 
population15,16. However, these studies do not discuss trends in non-opioid analgesic 
prescriptions among PLWH and do not describe progression to incident chronic opioid use. 
In this study, we compared trends in the prescription of both opioid and non-opioid 
analgesics among PLWH and individuals without HIV between 2001-2009. We looked at 
variations within these trends across age, sex, and state of residence. We then estimated 
the incidence of the development of chronic opioid therapy (COT), defined as ≥90 
consecutive days with an opioid prescription, among opioid-naïve individuals and 
determined the association between HIV and COT. 
Methods 
Study sample 
Data for this aim came from the Center for Medicare and Medicaid Services (CMS) 
Medicaid Analytic eXtract (MAX) claims files. Medicaid claims databases contain data on 
pharmaceutical prescriptions dispensed, clinical diagnoses, and medical service utilization 
from all billable healthcare interactions. The pharmaceutical data include comprehensive 
information on medications prescribed to Medicaid-eligible individuals, regardless of the 
prescribing physician. Because individuals receiving opioid medications occasionally seek 
prescriptions from multiple providers, a single database that captured all prescriptions was 
optimal for this analysis. A further benefit of the Medicaid database was the large volume of 
patients represented (over 50 million enrollees nationally). Finally, a large proportion 
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(approximately 40%17) of insured PLWH are covered under Medicaid, indicating that a 
Medicaid is a rich data source from which to glean information about healthcare utilization 
among PLWH. 
We analyzed data from 2001 through 2009, as these years represent a time period 
with a dramatic rise in the prevalence of opioid prescriptions and opioid overdose18, after 
which there has been a steady decline19. Additionally, several new guidelines and policy 
initiatives were developed during this time to address growing concerns about opioid 
use20. Therefore, we expected to observe interesting trends in the use of opioids during 
these years.  
We identified opioid and non-opioid oral analgesic prescriptions using the National 
Drug Code (NDC) coding system. The NDC was developed by the Food and Drug 
Administration (FDA) as part of Drug Listing Act of 1972 and provides a unique 10-digit 
number to all drugs available for commercial distribution in the United States. Using pre-
identified NDC codes (see Supplementary Table 1), we identified all pharmaceutical claims 
for opioid and non-opioid analgesics, along with the date prescribed and total days 
supplied, among our study sample from 2001-2009.  
We obtained demographic characteristics of the study participants, including age, 
sex, and state of residence, from the enrollment record of the MAX files. We identified 
medical conditions using the Johns Hopkins ACG® System 11.1, which applies propriety 
algorithms to identify chronic diseases using inpatient medical claims, pharmaceutical 
claims, and enrollment files. The ACG® System uses 12-month claims data to assess, 
annually, individual chronic conditions and to assign overall risk scores to individuals. In 
this analysis, we used five chronic conditions identified through the ACG® System, each of 
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which we hypothesized to be related to the receipt of prescription analgesics: HIV, 
diabetes, depression, schizophrenia, and bipolar disorder, and we used the categorical risk 
score, “major ADG count” as a summary measure for the individual’s overall chronic 
disease burden. 
The cohort analyzed in this study was originally assembled for the purpose of 
creating a comparison group for the North American AIDS Cohort Collaboration of 
Research and Design (NA-ACCORD) studies. Because we had access to these Medicaid files 
through NA-ACCORD, we chose to analyze this pre-assembled cohort. The sample included 
HIV-infected individuals between the ages of 18 and 65 years who were insured under 
Medicaid between 2001-2009 in one of 14 states: Alabama, California, Colorado, Florida, 
Georgia, Illinois, Massachusetts, Maryland, North Carolina, New York, Ohio, Pennsylvania, 
Texas, and Washington. The analytic cohort was assembled using a closed cohort of 
individuals who were enrolled in Medicaid on January 1, 2001. Individuals remained in the 
cohort for every month in which they were enrolled in Medicaid until December 31, 2009. 
Because the dataset comprised a closed cohort, data were not available on individuals who 
were new Medicaid enrollees after January 1, 2001.  
We excluded individuals with secondary insurance from the analysis, as Medicaid 
claims files do not contain information on prescriptions covered by other insurance. This 
exclusion criterion applied to individuals who had supplemental private insurance and 
those who were dual-eligible for both Medicaid and Medicare. Also, patients with gaps in 
coverage were excluded from the analysis for all years following the gap. Finally, we 
excluded patients from Florida because data were unavailable for all patients from Florida 
after 2001. Supplementary Table 2 shows the population of Medicaid enrollees by state in 
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the source population and Supplementary Table 3 shows the analytic sample size after the 
exclusion criteria were applied. 
Statistical methods 
We examined: 1) trends in opioid and non-opioid oral analgesic prescriptions over 
time and 2) the incidence of chronic opioid use comparing PLWH to individuals without 
HIV. The trends we examined included the standardized number of analgesic prescriptions 
per 100 individuals and the proportion of days covered by an opioid or non-opioid 
analgesic. All analyses were first conducted on the full analytic sample and then, to create a 
more homogenous study sample and consequently improve comparability between the HIV 
and non-HIV groups, we restricted the sample to a subset of patients with diabetes.  
Prevalence of opioid and non-opioid analgesics 
 
 To explore trends in opioid and non-opioid prescription oral analgesics over time, 
we created plots to depict the standardized rate of opioid and non-opioid analgesic 
prescriptions per 100 people by HIV status. We present the standardized rates of analgesic 
prescriptions among the full analytic sample and also among the diabetic subset. Also, to 
further ensure comparability between the HIV and non-HIV groups, we applied two sets of 
weights. First, we weighted the population to standardize the sample to the distribution of 
the characteristics among the HIV-infected individuals using inverse probability of HIV 
weights, as follows: PLWH were assigned a weight of 1 and individuals without HIV were 
given a weight corresponding to their estimated odds of having HIV according to a logistic 
regression model where HIV was modeled as a function of age, sex, state of residence, and 
major ADG count21. Second we calculated and applied inverse probability of censoring 
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weights (IPCW) to account for differential censoring by HIV status. We calculated the IPCW 
using a logistic regression model for Medicaid dis-enrollment as a function of year, age, sex, 
state of residence, major ADG count, and HIV status. 
In a second series of plots, we created boxplots by HIV status for the proportion of 
days covered (PDC) by opioid and non-opioid analgesic prescriptions (separately) among 
patients with at least one prescription opioid or non-opioid analgesic, respectively. All PDC 
boxplots display trends among the weighted study population, weighted by both IPTW and 
IPCW. We calculated PDC using SAS arrays and credited overlapping days supply by 
shifting the start date of prescriptions that began before the prior prescription ended22. We 
then describe the trends in opioid analgesics in more detail by showing boxplots stratified 
by age at baseline (18 to <35; 35 to <45; 45 to <55; 55 to <65), sex, and state of residence. 
We were unable to assess PDC for the state of Ohio because the number of days supplied 
per prescription was unavailable. Because we restricted these plots to patients with at least 
one opioid (or non-opioid), we also report the number and proportion of individuals in 
each year that received an opioid (or non-opioid) prescription.  
Incident chronic opioid therapy 
 
 We examined COT among opioid-naïve individuals. To create a subset of opioid-
naïve individuals, we identified and excluded all patients who received at least one opioid 
prescription during the first year of follow-up, as they represent prevalent opioid users. By 
implementing a one-year washout period, we were able to restrict the analysis to opioid-
naïve patients, thereby allowing us to assume that the first opioid prescription in the 
prescriptions claims records represents an incident opioid prescription. We weighted the 
population by the inverse probability of censoring weights to account for differential 
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dropout by HIV status. We accounted for differences in comorbidities by HIV status using 
regression adjustment. 
We examined the incidence of COT among a population of opioid-naïve individuals 
using a time-to-event analysis with a time origin defined as January 1, 2002. We defined 
COT using a standard definition of 90 continuous days with an opioid prescription23. 
Patients were followed until the first of: the 90th day of opioid therapy, loss of Medicaid 
coverage (due to a change in insurance status or death), or December 31, 2009.  
We plotted the cumulative incidence of COT using a Kaplan-Meier estimator and 
assessed the proportionality of the hazard of COT with respect to HIV-status. We then fit 
Cox proportional hazards models to estimate the crude and adjusted associations between 
HIV-status and COT among the weighted sample and among a subset of the weighted 
sample with diabetes. To ease computational burden, we selected a 10% random sample of 
the study population for the COT analyses. 
Results 
 The source population contained 15,856,135 individuals. After applying the 
exclusion criteria, the study population decreased to 4,561,139 individuals. Of these, 
54,120 (1.19%) had a diagnosis of HIV in 2001 and 288,027 (6.31%) had a diagnosis of 
diabetes in 2001. The sample size of the source population and eligible populations are 
shown by state in Supplementary Tables 2 and 3. 
 Within our analytic sample, PLWH differed from individuals without HIV with 
respect to most of the characteristics we measured. Slightly more than half (53%) of PLWH 
were male, whereas only 27% of individuals without HIV were male. PLWH were older, 
with a median age of 42 (IQR 37-38), compared to a median age of 34 (IQR 25-45) among 
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individuals without HIV. Regarding state of residence, the highest proportion of PLWH was 
from New York (44%), whereas the most represented state among individuals without HIV 
was California (37%). Approximately 42% of PLWH were prevalent opioid users in 2001, 
compared to only 24% of individuals without HIV. Finally, diabetes, depression, bipolar 
disorder, and schizophrenia, were all more common among PLWH, with prevalence rates of 
8%, 39%, 1%, and 3%, respectively, compared to prevalence rates of 6%, 17%, 0.4%, and 
1%. Table 1 describes characteristics of the study sample.  
Prevalence of opioid and non-opioid analgesics 
Opioid and non-opioid analgesic prescription rates by HIV status are shown in 
Figure 2 (opioids) and Figure 3 (non-opioids), where the left panel depicts the full sample 
and right panel is restricted to those with diabetes. The figures depict both unadjusted 
trends (dashed lines) and trends weighted by IPTW and IPCW (solid lines). In both panels, 
all analgesic prescriptions rise over time between 2001 and 2009.  
In unadjusted trends, PLWH received approximately twice the number of opioid 
analgesics compared to patients without HIV (Figure 2). When we applied the weights, 
trends in the non-HIV group increased causing PLWH to receive only 50-65% more opioid 
prescriptions compared to similar patients without HIV. Trends were more comparable 
among the diabetic subset: among the unadjusted sample with diabetes, PLWH received 
25-35% more opioid prescriptions compared to individuals without HIV. When we applied 
the weights, the difference by HIV status among diabetics decreased to about 13-15%.  
The absolute number of non-opioid analgesic prescriptions was higher than that of 
opioid prescriptions, but the patterns were similar: prescriptions increased over time in all 
groups, and the prevalence among PLWH was higher compared to individuals without HIV 
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(Figure 3). In unadjusted trends, the full sample of PLWH received approximately twice the 
number of non-opioid analgesics compared to patients without HIV; in weighted trends 
PLWH received about 20-30% more non-opioid analgesics. The difference by HIV status 
was less pronounced when restricting the sample to patients with diabetes, where PLWH 
received between 15-25% more non-opioid analgesic prescriptions compared to their non-
HIV infected counterparts in unadjusted trends. Among the weighted diabetic subset, the 
prevalence of non-opioid analgesics was similar by HIV status until 2004, at which point 
PLWH received approximately 10% more non-opioid analgesic prescriptions.  
Proportion of days covered 
The proportion of individuals receiving an opioid analgesic was higher among 
PLWH compared to individuals without HIV. After weighting by IPTW and IPCW, the 
proportion of PLWH receiving at least one opioid prescription increased from 43.9% in 
2001 to 49.6% in 2009. The corresponding proportion among patients without HIV was 
29.0% in 2001 and 40.1% in 2009 (Table 2).  
Not only were PLWH more likely to receive opioid prescriptions, but when 
examining only patients who received at least one opioid prescription, PLWH also had a 
higher proportion of total days covered (PDC) by an opioid. The PDC increased each year, 
from a mean of 0.24 among PLWH and 0.19 among people without HIV in 2001 to 0.34 and 
0.28 in 2009 among patients with and without HIV, respectively (Figure 4). The PDC was 
slightly higher among the diabetic subset, as seen in the right panel of Figure 4. 
Overall, more individuals received non-opioid analgesic prescriptions compared to 
opioid analgesics; however, like the opioid analgesic prescriptions, a higher proportion of 
PLWH received non-opioid analgesics compared to individuals without HIV. In the 
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weighted study sample, 54.8% of PLWH and 39.4% of individuals without HIV received a 
non-opioid analgesic in 2001. By 2009, 59.4% and 51.6% of PLWH and individuals without 
HIV, respectively, received a non-opioid analgesic (Table 3).  
Compared to the PDC of opioid analgesics, the difference in PDC for non-opioid 
analgesic prescriptions between PLWH and individuals without HIV was less pronounced. 
When looking at patients who received at least one non-opioid analgesic in the weighted 
study sample, the mean PDC for non-opioids among PLWH increased from 0.33 in 2001 to 
0.43 in 2009. Among individuals without HIV, the mean PDC increased from 0.35 in 2001 to 
0.41 in 2009. Mean and median PDC values both increased when we restricted the sample 
to diabetic patients only. Figure 5 provides more detail on the trends in PDC for non-opioid 
analgesic prescriptions. 
Proportion of days covered: stratified  
We stratified the PDC analysis for opioid prescriptions to determine whether the 
trends vary by age, sex, and/or state of residence. As above, we applied IPTW and IPCW to 
account for differences in comorbidities and Medicaid dropout by HIV status. Figure 6 
displays the proportion of days covered by age category, with Table 4 describing the 
sample size depicted in the figure. Figure 7 (and Table 5) show trends by sex, and Figure 8 
(and Table 6) shows the trends by state. 
The highest proportion of PLWH receiving at least one opioid were aged 35-55 
years (approximately 45% in 2001 and 51.5% in 2009), whereas the highest proportion of 
patients without HIV who received at least one opioid prescription were 45-64 years old 
(36.9% in 2001 and 45.2% in 2009) (Table 4). Among those receiving at least one opioid 
prescription, the distribution of the proportion of days covered was highest among patients 
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aged 45-55 years, regardless of HIV status (mean among PLWH: 0.31 in 2001 to 0.41 in 
2009; mean among people without HIV: 0.25 in 2001 to 0.34 in 2009).  The lowest 
proportion of days covered occurred among patients between the ages of 18 and 35 years 
(mean among PLWH: 0.15 in 2001 to 0.25 in 2009; mean among people without HIV: 0.09 
in 2001 to 0.19 in 2009). Figure 6 shows trends in the distribution of PDC by HIV status in 
the four age categories.  
Females were more likely than males to receive an opioid analgesic, regardless of 
HIV status. In 2001, 47.1% of females with HIV and 30.6% of females without HIV received 
at least one opioid prescription, compared to 38.7% and 27.4% of males with and without 
HIV, respectively. In 2009, the proportion of females with and without HIV receiving at 
least one opioid prescription increased to 51.8% and 43.6%, respectively. Among males, 
the proportion increased to 46.5% and 36.6% among those with and without HIV, 
respectively (Table 5). Despite being more likely to receive an opioid prescription, women 
did not have a higher PDC compared to men. Among females receiving at least one opioid 
prescription, the mean PDC in 2001 was 0.22 among PLWH and 0.17 among women 
without HIV, and increased to 0.31 among PLWH and 0.26 among women without HIV in 
2009 (Figure 7, left panel). Among males receiving at least one opioid prescription, the 
mean PDC among people with and without HIV was 0.26 and 0.22, respectively, in 2001 
and increased to 0.38 and 0.30, respectively, in 2009 (Figure 7, right panel). 
Among our sample of 12 states (Ohio was excluded due to missing data on opioid 
days supplied), there was considerable variation both in the proportion of individuals with 
at least one opioid prescription and in the PDC among those with at least one opioid 
prescription. Generally, the proportion of individuals receiving at least one opioid 
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prescription increased over time, and the proportion PLWH receiving at least one opioid 
prescription was higher than the proportion among individuals without HIV. Table 6 shows 
the proportion of individuals in each state receiving at least one opioid prescription by 
year; it is important to note the small sample size (particularly among the PLWH group) in 
some states, including Alabama, Colorado, Pennsylvania, and Washington. As seen in Figure 
8, the PDC among individuals with at least one opioid prescription was usually larger in 
among PLWH; however, the reverse was true in Alabama, Georgia, North Carolina, 
Maryland, and occasionally Pennsylvania and Texas. 
Incident chronic opioid therapy 
 We selected a 10% random sample containing 456,199 individuals enrolled in 2001 
as the analytic sample for the incidence of COT. Of these individuals, 110,565 (24.2%) were 
prevalent opioid users in 2001 and were excluded from the analysis. We excluded an 
additional 121,837 individuals with no follow-up after 2001. The final analytic sample for 
the incident COT analysis included 223,797 opioid-naïve individuals who contributed 
940,329 person-years of follow-up. The diabetic subset contained 13,383 patients who 
contributed 78,376 person-years of follow-up. 
Overall, 9,049 individuals (4.0%) progressed to COT during the 8-year follow-up 
period for an incidence rate of 9.6 per 1,000 person-years. Among PLWH, 448 individuals 
(incidence rate: 29.1 per 1,000 person-years) developed COT compared to 8,601 
individuals without HIV (incidence rate: 9.3 per 1,000 person-years). Among patients with 
diabetes, 2,246 individuals (16.8%) progressed to COT for an incidence rate of 28.7 per 
1,000 person-years; 69 of whom were living with HIV (incidence rate: 43.7 per 1,000 
person-years) compared to 2,177 without HIV (incidence rate: 28.3 per 1,000 person-
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years). Figure 9 and Figure 10 show the Kaplan-Meier estimated cumulative incidence of 
COT by HIV status, weighted by IPCW, for the full and diabetic subsamples, respectively.  
 In an IPCW-weighted unadjusted Cox proportional hazards model, people with HIV 
had 3.06 times the hazard for COT compared to patients without HIV (95% CI 2.76-3.39). 
After adjusting for age, sex, and state of residence, the increased hazard among people 
living with HIV decreased to 2.37 (95% CI 2.13-2.63). Further adjusting for major ADG 
count, bipolar disorder, depression, and schizophrenia, the hazard ratio comparing PLWH 
to patients without HIV was 1.46 (95% CI 1.31-1.63). The results of the Cox proportional 
hazards models are shown in Table 7. 
 Among the weighted subset of individuals with diabetes, PLWH had 1.61 (95% CI 
1.25-2.09) times the hazard of COT compared to diabetics without HIV in an unadjusted 
Cox proportional hazards model. The hazard was slightly higher after adjusting for age, sex, 
and state of residence (aHR=1.72, 95% CI 1.32-2.23), but became smaller and statistically 
non-significant after further adjusting for major ADG count, bipolar disorder, depression, 
and schizophrenia (aHR=1.26, 95% CI 0.97-1.63).  Table 8 shows the results of the Cox 
proportional hazards models among the subset of patients with diabetes. 
Discussion 
 In our sample of approximately 4.5 million Medicaid enrolled individuals, we found 
an increasing rate of all prescription oral analgesics, both opioid and non-opioid, from 2001 
and 2009 regardless of HIV status. The annual number of opioid prescriptions dispensed at 
the start of our study averaged to slightly more than one per person among the HIV 
uninfected population and approximately 2.5 per person among PLWH in 2001, and 
increased to approximately 2 per person among HIV uninfected individuals and nearly 4 
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per person among PLWH in 2009. The dramatic increase in opioid dispensing is 
concerning, as an increase in the availability of opioids may lead to an increased rate of 
opioid abuse and overdose.  
Not only did we find an increase in opioid prescriptions, but we also found a similar 
increase in non-opioid analgesic prescriptions over the same time period. This may be a 
reflection of providers first prescribing non-opioid analgesics to patients requesting opioid 
treatment for pain. The similar increase in all analgesic prescriptions may also reflect a 
secular trend in the United States towards pharmaceuticals. As interventions are being 
implemented across the United States to reduce inappropriate opioid prescribing and 
reduce the consequences of opioid misuse, we would hope to observe an increase in non-
opioid analgesics with a simultaneous decrease in opioid prescriptions as providers tend 
towards non-opioid treatments. 
In all years, PLWH received a higher number of analgesic prescriptions compared to 
individuals without HIV. However, the characteristics of PLWH and individuals without HIV 
varied considerably. Weighting the study population and restricting the sample to patients 
with diabetes helped to reduce heterogeneity in the sample, and also diminished the 
differences in number of analgesic prescriptions, suggesting that the differential 
prescription rates may be due largely to differences in age, sex, and co-morbidities between 
the populations. Our weighted diabetic subsample was designed to further remove 
heterogeneity by HIV status, allowing us to assume approximately equal rates of chronic 
pain in the two comparison groups. Because we found similar, and even slightly higher, 
rates of analgesic prescriptions among PLWH after accounting for demographic and clinical 
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characteristics, we do not have evidence to support a systematic under-treatment of pain 
among PLWH. 
The distribution of opioids dispensed is highly skewed, with a large proportion of 
individuals receiving no prescriptions, and small proportion (top 25th percentile of those 
receiving at least one prescription) receiving very high numbers of opioids. Even when 
excluding individuals who received no opioid prescriptions (all boxplots were restricted to 
patients with at least one opioid prescription), the median PDC was notably smaller than 
the mean across all years and all strata. The skewed distribution is important to note when 
interpreting the number of analgesics dispensed per 100 individuals, as the high number of 
prescriptions dispensed to the few individuals who receive the most prescriptions affects 
the standardized rate of opioid prescriptions.  
Compared to a recently published study examining trends in opioid prescribing 
between 2006-201619, we observed a higher number of opioids prescribed per capita. This 
is likely due in part to the characteristics of our study population: specifically, that our 
study population was drawn from a population of Medicaid-enrolled individuals who have 
higher rates of co-morbidities compared to the general population. Despite finding higher 
absolute numbers of prescriptions per capita than the 2017 publication, the trends we 
observed regarding the dramatic increase in prescribing rates through 2009 were 
consistent. Because of the similar trajectory we observed in our population compared to 
recently measured trends, we would expect to see a similar stabilization in opioid 
prescriptions among Medicaid enrolled PLWH beyond 2009, if we were to extrapolate the 
trends beyond the timeframe of this analysis. 
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 Trends by age and sex were consistent throughout our study, with females being 
more likely to receive an opioid prescription and having a statistically significant higher 
incidence of COT compared to males. We observed a higher prevalence of opioid use and a 
higher incidence of COT among individuals who were older at study baseline. These trends 
by age and sex, are consistent with prior literature on opioid dispensing patterns across the 
United States24,25, although they differ from trends examining opioid misuse and overdose, 
supporting studies that report additional characteristics on the causal pathway between 
receiving an opioid prescription and developing opioid misuse26. In other words, receiving 
a larger quantity of opioids is not, in itself, sufficient to predict an increased likelihood for 
misuse. 
 We observed significant variability in opioid prescribing trends by state, which 
follows logically due to the varying Medicaid eligibility requirements by state (resulting in 
demographic, socioeconomic, and clinical differences in the analytic sample by state) and 
also to differences in state policies regarding opioid prescribing, namely prescription drug 
monitoring programs. In a 2006 study of geographic variability in opioid prescribing, Curtis 
et al. also found significant variation in rates of opioid prescriptions across the United 
States11, though the population analyzed in this study comprised commercially insured 
individuals, resulting in slightly different trends than we observed in our Medicaid-enrolled 
sample. McDonald et al. also found higher than expected variation in opioid prescribing 
between states, with more opioids being prescribed in Appalachian, southern, and western 
states27. Zerzan et al., who also studied opiate use among a Medicaid population, report 
large increases in opioid prescriptions between 1996-2002 and found unexplained 
geographic variation28. 
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Developing chronic opioid use was fairly uncommon among all opioid-naïve 
individuals, which is consistent with prior literature24, but it was significantly more likely 
among PLWH compared to individuals without HIV. The increased hazard for COT among 
PLWH persisted, though the magnitude decreased, after adjusting for demographic and 
clinical characteristics and diminished even further when we restricted the sample to 
patients with diabetes. These findings suggest that the increased hazard of COT among 
PLWH is due primarily to differences in co-morbidities among PLWH and disparities in 
people who acquired HIV during the timeframe of our study. In other words, we did not 
find evidence to suggest differential treatment among patients by HIV status alone; 
however, we did find that PLWH are more likely than the general population to have 
chronic conditions requiring COT. Awareness about the proper treatment of pain among 
PLWH and recommendations for appropriate opioid prescribing are important in the 
treatment of PLWH. 
 The sample of PLWH included in our analysis differs from the general population of 
PLWH across the United States. Most notably, our sample of PLWH was nearly 50% female, 
whereas the US population of PLWH is approximately 25% female29. The 
overrepresentation of women in our study sample is likely due to Medicaid’s more lenient 
eligibility requirements during pregnancy and the increased likelihood for single mothers 
with dependents to meet the income threshold for Medicaid enrollment. Because our study 
population includes only Medicaid-enrolled individuals, our results are most applicable to 
populations of lower socioeconomic status rather than all PLWH. Further, our study sample 
was unique in that we analyzed a closed cohort of individuals who were continuously 
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enrolled in Medicaid during our follow-up period. It is possible that the characteristics of 
individuals who remained in our study differ from those of a dynamic Medicaid population. 
 There were some limitations to this study. First, we were limited in our ability to 
examine absolute trends in opioid prescriptions over time, as our sample was drawn from 
a closed cohort of Medicaid-enrollees. However, the primary focus of this analysis was to 
compare trends by HIV status, so the absence of data on the absolute number of 
prescriptions is did not preclude the analysis. Next, we were unable to measure the 
prevalence of a large portion of non-opioid analgesics, as a majority of non-opioid 
analgesics are purchased over-the-counter and do no appear in Medicaid prescription 
claims files. Similarly, we did not know the indication for the non-opioid analgesics 
prescribed; many of the non-opioid analgesics included in the analysis have non-pain 
related indications and are only occasionally used off-label to treat pain. We report the 
proportion of the non-opioid analgesics included in the analysis that is primarily used for 
pain (i.e. NSAIDs) versus anticonvulsants, anti-depressants, and muscle relaxants in 
Supplementary Table 4. 
 Despite the limitations, our study also incorporated several strengths. First, we 
analyzed a large sample of patients and were able to examine a comprehensive list of all 
prescriptions dispensed to our study sample. The closed cohort allowed us to follow the 
same individuals over time, enabling the examination of progression to COT among opioid-
naïve individuals. Also, despite being unable to measure over-the-counter medications, we 
did attempt to account for alternative analgesic treatments by examining prescription non-
opioid analgesic medications. Finally, by using only Medicaid-eligible participants 
(Medicaid eligibility criteria varies by state, but in all cases requires individuals to earn 
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below a threshold income, often below 138% of the federal poverty level30), we restricted 
our population to a particular socioeconomic subset of the US population that was of 
interest for this study. This helps mitigate residual confounding that was likely present due 
to our inability to adjust for unmeasured socio-demographic and behavioral 
characteristics. 
Overall, the trends we observed in analgesic prescription rates do not support an 
under-treatment of pain among PLWH. In fact, we found that PLWH were more likely to 
receive opioid analgesics and, when they did receive opioids, they received greater 
numbers than individuals without HIV. The increased proportion of days covered by an 
opioid among PLWH may be due to a higher prevalence of pain in these individuals; 
however, the similarity by HIV status in the standardized number of opioid prescriptions 
after accounting for demographic and clinical differences, and the higher incidence of COT 
among PLWH after adjustment for confounders suggest that PLWH receive at least equal, if 
not greater, opioid therapy compared to their HIV-uninfected counterparts. Pain is highly 
prevalent among PLWH; focusing on the appropriate treatment of chronic pain, especially 
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Table 1: Baseline demographic characteristics 
Characteristics of the analytic study sample in 2001 by HIV status; N=4,561,139 





















































































Diabetes 4,540 (8.39) 283,487 (6.29) 
Depression 21,022 (38.84) 767,935 (17.04) 
Bipolar 625 (1.15) 18,242 (0.40) 
Schizophrenia 1,568 (2.90) 41,478 (0.92) 
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Table 2: Number and proportion of individuals with at least one prescription opioid 
analgesic in each year, among full sample and diabetic subset, weighted  
Full Sample 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 15,924.6 12,270.5 13,986.4 15,540.5 16,862.9 18,339.1 19,773.2 20,636.3 21,393.8 
% 43.90 40.92 42.24 43.65 44.87 45.63 47.17 48.92 49.55 
No 
HIV 
N 12,317.1 9,820.8 12,047.4 14,081.7 16,123.5 18,278.9 19,869.0 20,892.8 22,220.7 
% 28.99 29.39 31.32 33.07 35.19 36.51 37.36 38.79 40.09 
Diabetic subset 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 1,563.2 1,363.8 1,744.8 2,163.2 2,538.6 2,987.8 3,504.9 3,837.2 4,154.3 
% 51.69 48.42 48.35 49.70 50.80 51.51 53.89 55.81 57.14 
No 
HIV 
N 2,428.5 2,079.5 2,824.1 3,528.9 4,241.1 5,092.0 5,815.3 6,198.9 6,579.5 
% 47.62 45.26 46.68 47.97 49.59 50.63 51.30 52.38 53.46 
 
Table 3: Number and proportion of individuals with at least one prescription non-
opioid analgesic in each year, among full sample and diabetic subset, weighted  
Full Sample 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 19,874.1 16,483.9 18,555.1 20,423.7 21,627.8 22,934.1 24,320.7 24,878.1 25,645.9 
% 54.79 54.97 56.03 57.37 57.55 57.07 58.02 58.97 59.40 
No 
HIV 
N 16,735.4 14,314.1 17,469.1 20,240.6 22,419.3 24,682.1 26,536.8 27,330.2 28,553.9 
% 39.38 42.84 45.41 47.53 48.93 49.30 49.90 50.74 51.56 
Diabetic subset 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 2,042.3 1,893.7 2,444.8 3,010.7 3,436.8 3,980.4 4,543.1 4,854.5 5,147.7 
% 67.53 67.23 67.64 69.17 68.78 68.63 69.85 70.61 70.80 
No 
HIV 
N 3,379.8 3,070.2 4,119.0 5,132.6 5,902.6 6,782.6 7,681.8 8,052.8 8,392.2 




Table 4: Number and proportion of individuals with at least one prescription opioid 
analgesic in each year, by age at baseline, weighted 
Age 18-34 at baseline 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 3,910.0 2,876.4 3,434.2 4,002.9 4,535.6 5,145.5 5,616.6 6,187.4 6,727.7 
% 43.29 39.28 40.22 41.49 42.56 43.16 44.23 46.06 46.57 
No HIV 
N 3,434.9 2,645.5 3,257.1 3,868.2 4,610.4 5,426.5 5,880.8 6,636.5 7,614.0 
% 20.37 21.78 23.61 25.39 27.81 29.23 30.00 32.13 34.20 
Age 35-44 at baseline 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 7,026.0 5,450.0 6,302.6 6.953.2 7,548.7 8,211.4 8,960.5 9,332.9 9,733.1 
% 45.01 41.64 43.72 44.85 46.13 46.99 48.92 50.58 51.54 
No HIV 
N 2,719.3 2,390.3 3,021.9 3,652.0 4,346.8 5,091.7 5,752.1 6,278.0 6,911.0 
% 30.53 30.20 32.35 34.10 36.57 38.05 39.26 41.23 42.77 
Age 45-54 at baseline 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 4,129.0 3,318.8 3,599.6 3,932.0 4,170.4 4,442.9 4,759.1 4,864.0 4,849.3 
% 44.04 41.85 42.33 44.29 45.59 46.40 47.83 49.81 50.25 
No HIV 
N 3,206.2 2,752.9 3,526.0 4,272.1 5,004.1 5,909.1 6,686.1 7,027.6 7,346.5 
% 36.88 35.95 37.82 39.51 41.36 42.61 43.50 44.39 45.24 
Age 55-64 at baseline 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 859.5 625.4 650.0 652.4 608.1 539.3 436.0 252.0 82.6 
% 38.10 37.99 39.24 41.50 43.08 44.40 46.10 47.36 43.83 
No HIV 
N 2,956.7 2,032.0 2,242.2 2,289.2 2,161.8 1,950.9 1,548.9 949.4 327.9 
% 36.82 35.69 37.33 39.34 41.12 42.51 43.61 44.29 46.00 
 
 
Table 5: Number and proportion of individuals with at least one prescription opioid 
analgesic in each year, by sex, weighted 
Female 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 8,231.3 5,975.3 7,034.5 7,898.6 8,830.1 9,566.4 10,471.3 11,155.6 11,742.0 
% 47.06 43.47 44.70 45.45 47.14 47.06 48.92 50.78 51.78 
No HIV 
N 6,509.0 5,081.9 6,367.4 7,519.7 8,645.6 9,814.6 10,600.3 11,274.9 12,104.2 
% 30.61 32.13 33.99 35.61 38.03 39.71 40.58 42.15 43.59 
Male 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 7,693.3 6,295.3 6,952.0 7,642.0 8,032.8 8,772.7 9,301.9 9,480.6 9,651.9 
% 38.70 38.27 39.30 41.13 41.86 43.32 44.40 46.07 46.45 
No HIV 
N 5,808.1 4,738.9 5,680.0 6,562.1 7,478.0 8,464.3 9,268.6 9,618.0 10,096.6 




Table 6: Number and proportion of individuals with at least one prescription opioid 
analgesic in each year, by state, weighted 
Alabama 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 124.8 142.8 167.6 199.2 213.1 238.6 258.6 262.4 293.5 
% 54.01 50.22 52.73 55.24 55.72 58.45 61.37 61.70 64.22 
No HIV 
N 112.0 130.5 166.2 199.1 214.6 244.6 264.8 261.2 260.5 
% 41.04 40.38 40.74 41.26 42.83 53.30 56.09 55.43 56.01 
California 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 1,984.3 2,497.7 2,883.3 3,086.2 3,213.4 3,533.6 3,892.4 3,947.0 3,862.4 
% 50.58 53.06 54.06 53.74 52.70 54.07 55.20 55.69 53.39 
No HIV 
N 1,228.1 1,484.7 1,946.5 2,189.4 2,249.2 2,559.3 2,857.6 2,962.6 2,919.5 
% 24.35 24.85 28.06 30.14 30.36 32.04 33.66 35.45 35.64 
Colorado 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 32.0 25.3 30.7 42.9 54.3 59.5 73.9 66.2 65.2 
% 52.83 37.44 38.96 50.61 54.29 48.09 56.71 51.48 47.91 
No HIV 
N 19.0 21.7 36.6 40.5 45.4 58.2 71.1 76.7 77.8 
% 25.11 25.75 34.69 37.10 37.00 43.78 47.19 50.13 49.62 
Georgia 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 543.6 578.5 694.6 779.9 802.8 843.6 812.0 942.5 1,011.9 
% 53.81 51.68 56.34 57.87 57.00 57.26 53.87 59.54 60.64 
No HIV 
N 542.6 618.4 816.7 965.9 1,035.2 1,095.8 1,054.9 1,194.1 1,258.0 
% 50.92 52.39 56.04 56.65 57.63 57.18 52.02 58.36 60.46 
Illinois 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 613.5 681.5 768.7 842.5 909.8 976.4 1,024.3 1,089.0 1,153.8 
% 43.52 43.18 45.00 45.64 46.73 47.95 47.81 47.86 50.13 
No HIV 
N 459.6 576.4 729.0 872.5 954.6 1,083.9 1,194.7 1,390.9 1,519.4 
% 30.88 36.72 39.08 40.86 41.84 43.31 44.71 42.57 46.07 
Massachusetts 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 652.9 762.9 817.1 938.3 1,047.6 1,186.4 1,303.8 1,297.5 1,374.5 
% 47.00 46.74 45.21 46.49 47.53 48.66 50.50 49.80 49.71 
No HIV 
N 580.5 602.9 641.7 766.6 878.4 992.7 1,147.1 1,142.6 1,227.3 
% 30.74 31.13 32.19 32.66 33.75 33.77 35.71 35.68 36.62 
Maryland 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 646.6 698.1 655.8 801.1 986.7 1,138.6 1,353.3 1,428.1 1,566.0 
% 43.87 42.28 37.18 42.66 47.94 50.48 56.58 58.84 61.17 
No HIV 
N 496.9 570.9 585.2 748.0 1,014.9 1,199.1 1,357.5 1,475.2 1,743.9 
% 27.89 29.75 27.41 32.04 38.72 43.09 47.38 51.14 54.17 
North Carolina 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 488.6 546.2 602.7 648.2 676.2 695.9 798.9 841.7 891.8 
% 53.02 54.22 56.50 57.10 57.96 56.15 61.09 62.07 65.12 
No HIV 
N 480.7 567.4 697.5 802.1 872.0 1,007.4 1,080.1 1,107.3 1,143.2 




 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 4,253.4 4,967.1 5,878.2 6,560.5 7,288.0 7,867.4 8,403.4 8,980.6 9,392.3 
% 33.40 33.83 35.93 37.33 39.39 39.83 41.43 44.46 45.82 
No HIV 
N 3,293.3 4,042.4 4,940.7 5,794.3 7,002.7 7,890.1 8,638.3 9,207.9 9,971.3 
% 24.78 25.15 26.89 28.46 31.42 32.27 33.32 35.18 36.69 
Pennsylvania 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 180.5 114.2 89.2 97.8 111.2 103.3 115.3 117.6 123.6 
% 17.61 12.23 9.66 10.27 11.35 10.42 11.63 12.31 12.97 
No HIV 
N 122.1 116.9 126.2 148.4 161.0 186.9 211.4 212.4 217.6 
% 14.75 13.47 12.47 12.95 13.08 13.86 14.55 14.88 15.17 
Texas 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 673.3 817.6 917.4 1,014.0 994.8 1,080.0 1,223.0 1,244.6 1,256.5 
% 49.27 52.50 54.16 57.27 55.23 56.19 58.99 59.40 59.62 
No HIV 
N 632.4 749.1 920.9 1,036.5 1,104.2 1,259.6 1,470.4 1,449.8 1,495.6 
% 42.97 46.06 47.63 48.10 49.02 50.39 51.84 51.38 53.26 
Washington 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
N 114.8 108.9 134.6 152.2 158.1 188.9 213.3 193.1 183.3 
% 56.68 51.74 54.55 56.11 56.06 58.62 59.24 52.81 43.56 
No HIV 
N 70.7 75.1 107.0 127.1 144.0 221.7 233.9 222.9 176.9 





Table 7: Development of chronic opioid therapy among opioid-naïve individuals 
Cox proportion hazards model for the development of chronic opioid therapy among 
opioid-naïve individuals between January 1, 2002 and December 31, 2009; sample selected 
from a 10% random sample of eligible study population; N=223,797 individuals 
contributing 940,329 person-years of follow-up. Adjusted Model 1: adjusted for categorical 
age, sex, and state of residence (Ohio excluded due to missing data on opioid days 
supplied). Adjusted Model 2: adjusted for categorical age, sex, state of residence, major ADG 
count, bipolar disorder, schizophrenia, and depression. All models weighted by the inverse 
probability of censoring. 
 Hazard Ratio (95% CI) 
 Unadjusted Model Adjusted Model 1 Adjusted Model 2 
HIV 3.06 (2.76-3.39) 2.37 (2.13-2.63) 1.46 (1.31-1.63) 
Age 
18 to <35 
35 to <45 
45 to <55 









































































Bipolar disorder -- -- 0.83 (0.73-0.94) 
Schizophrenia -- -- 0.41 (0.38-0.46) 





Table 8: Development of chronic opioid therapy among opioid-naïve diabetics 
Cox proportion hazards model for the development of chronic opioid therapy among 
opioid-naïve diabetics between January 1, 2002 and December 31, 2009; sample selected 
from a 10% random sample of eligible study population; weighted by inverse probability of 
censoring weights; N=13,383 individuals contributing 78,376 person-years of follow-up. 
Adjusted Model 1: adjusted for categorical age, sex, and state of residence (Ohio excluded 
due to missing data on opioid days supplied). Adjusted Model 2: adjusted for categorical 
age, sex, state of residence, major ADG count, bipolar disorder, schizophrenia, and 
depression. All models weighted by the inverse probability of censoring. 
 Hazard Ratio (95% CI) 
 Unadjusted Model Adjusted Model 1 Adjusted Model 2 
HIV 1.61 (1.25-2.09) 1.72 (1.32-2.23) 1.26 (0.97-1.63) 
Age 
18 to <35 
35 to <45 
45 to <55 









































































Bipolar disorder -- -- 0.72 (0.57-0.92) 
Schizophrenia -- -- 0.46 (0.38-0.54) 





Figure 2: Opioid Analgesic Prescriptions per 100 People 
Total number of opioid analgesic prescriptions dispensed between 2001-2009 per 100 
people, by HIV status; left panel: full analytic sample; right panel: restricted to patients with 
diabetes only; dashed lines depict unadjusted trends; solid lines depict trends weighted by 





Figure 3: Non-Opioid Analgesic Prescriptions per 100 People 
Total number of non-opioid analgesic prescriptions dispensed between 2001-2009 per 100 
people, by HIV status; left panel: full analytic sample; right panel: restricted to patients with 
diabetes only; dashed lines depict unadjusted trends; solid lines depict trends weighted by 




Figure 4: Proportion of Days Covered by an Opioid Analgesic, weighted 
Proportion of days covered by an opioid analgesic prescription among individuals with at 
least one opioid analgesic prescription in the given year, weighted by inverse probability of 
HIV and by the inverse probability of censoring (left panel: all individuals; right panel: 
diabetic subset). The shaded box depicts the interquartile range, the whiskers indicate the 
minimum and maximum values, the horizontal line shows the median, and the open circle 
(HIV group) or cross (non-HIV group) shows the mean. The table below the x-axis displays 
the proportion of individuals in each year with at least one opioid prescription. Table 2 
describes the sample size and overall proportion of individuals with an opioid in each year.  
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Figure 5: Proportion of Days Covered by a Non-Opioid Analgesic, weighted 
Proportion of days covered by a non-opioid analgesic prescription among individuals with 
at least one non-opioid analgesic prescription in the given year, weighted by inverse 
probability of HIV and by the inverse probability of censoring (left panel: all individuals; 
right panel: diabetic subset). The shaded box depicts the interquartile range, the whiskers 
indicate the minimum and maximum values, the horizontal line shows the median, and the 
open circle (HIV group) or cross (non-HIV group) shows the mean. The table below the x-
axis displays the proportion of individuals in each year with at least one non-opioid 
prescription. Table 3 describes the sample size and overall proportion of individuals with a 
non-opioid in each year.  
 





Figure 6: Proportion of Days Covered by an Opioid Analgesic, by age at baseline, 
weighted 
Proportion of days covered by an opioid analgesic prescription among individuals with at 
least one opioid analgesic prescription in the given year, stratified by age at baseline, 
weighted by inverse probability of HIV and by the inverse probability of censoring. The 
shaded box depicts the interquartile range, the whiskers indicate the minimum and 
maximum values, the horizontal line shows the median, and the open circle (HIV group) or 
cross (non-HIV group) shows the mean. The table below the x-axis displays the proportion 
of individuals in each year with at least one opioid prescription. Table 4 describes the 







Figure 7: Proportion of Days Covered by an Opioid Analgesic, by sex, weighted 
Proportion of days covered by an opioid analgesic prescription among individuals with at 
least one opioid analgesic prescription in the given year, stratified by sex, weighted by 
inverse probability of HIV and by the inverse probability of censoring. The shaded box 
depicts the interquartile range, the whiskers indicate the minimum and maximum values, 
the horizontal line shows the median, and the open circle (HIV group) or cross (non-HIV 
group) shows the mean. The table below the x-axis displays the proportion of individuals in 
each year with at least one opioid prescription. Table 5 describes the sample size and 




Figure 8: Proportion of Days Covered by an Opioid Analgesic, by state, weighted 
Proportion of days covered by an opioid analgesic prescription among individuals with at 
least one opioid analgesic prescription in the given year, stratified by state of residence, 
weighted by inverse probability of HIV and by the inverse probability of censoring. The 
shaded box depicts the interquartile range, the whiskers indicate the minimum and 
maximum values, the horizontal line shows the median, and the open circle (HIV group) or 
cross (non-HIV group) shows the mean. The table below the x-axis displays the proportion 
of individuals in each year with at least one opioid prescription. Table 6 describes the 





Figure 9: Kaplan-Meier estimate for the incidence of chronic opioid therapy, 
weighted 
Cumulative incidence of the development of chronic opioid therapy (COT) among a sample 
of opioid-naïve individuals followed from January 1, 2002 until the first day of COT 
(defined as the 90th day of consecutive opioid use), Medicaid dis-enrollment, or December 






Figure 10: Kaplan-Meier estimate for the incidence of chronic opioid therapy among 
diabetics, weighted 
Cumulative incidence of the development of chronic opioid therapy (COT) among a sample 
of opioid-naïve diabetics followed from January 1, 2002 until the first day of COT (defined 
as the 90th day of consecutive opioid use), Medicaid dis-enrollment, or December 31, 2009, 







Supplementary Table 1: Summary of pre-defined NDCs used to identify opioid and 
non-opioid analgesics 
Number of unique NDCs used to define each category of analgesic. Actual NDCs not listed. 
Opioid Analgesics 
Drug Type Total number of NDCs included 
Hydrocodone 4354 
Codeine 1849 
Oxycodone SA 1466 
Propoxyphene 1385 
Tramadol 1094 
Morphine LA 681 
Morphine SA 618 
Hydromorphone 456 
Oxycodone LA 312 
Fentanyl LA 209 
Methadone 206 
Fentanyl SA 144 
Pentazocine 137 










Non-Opioid Analgesics: NSAIDS 




Naproxen Sodium 1039 
















Fenoprofen Calcium 237 
Meclofenamate Sodium 199 
Diclofenac Potassium 176 
Mefenamic Acid 66 
Magnesium Salicylate 57 
Flurbiprofen Sodium 15 
Indomethacin Sodium 12 
Acetaminophen/Caffeine/Magnesium Salicylate 6 
Aspirin/Butalbital 5 
Diclofenac 2 
Aspirin /Phenobarbital 1 
Non-Opioid Analgesics: Anti-depressants 
Drug Type Total number of NDCs included 
Amitriptyline Hydrochloride 1808 
Doxepin Hydrochloride 909 
Venlafaxine Hydrochloride 870 
Imipramine Hydrochloride 667 
Desipramine Hydrochloride 497 
Duloxetine Hydrochloride 317 
Maprotiline Hydrochloride 150 
Amoxapine 134 
Clomipramine Hydrochloride 113 
Trimipramine Maleate 88 
Imipramine Pamoate 67 
Protriptyline Hydrochloride 34 
Milnacipran Hydrochloride 27 
Desvenlafaxine Succinate 23 
Desvenlafaxine 20 
Levomilnacipran Hydrochloride 9 
Non-Opioid Analgesics: Anticonvulsants 









Valproic Acid 183 
Zonisamide 156 
Tiagabine Hydrochloride 99 
Phenytoin 74 
Lacosamide 13 
Non-Opioid Analgesics: Muscle relaxants 
















Supplementary Table 2: Source Population by State 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
AL  400,608   348,109   308,529   284,698   265,084   247,037   195,232   180,105   170,777  















CO  189,420   143,828   116,024   105,290   99,810   90,385   82,550   76,655   73,157  
FL  1,236,264   890   546   550   542   517   479   450   446  
GA  608,229   449,141   370,809   339,324   310,339   282,338   256,794   241,086   226,566  
IL  805,222   648,861   541,168   508,632   484,525   458,480   429,051   407,705   390,183  
MA  691,563   601,136   498,035   435,617   410,807   390,440   370,821   384,353   373,180  
MD  317,805   267,998   231,751   200,770   179,901   160,791   141,484   133,328   134,777  
NC  708,849   541,111   463,805   420,910   384,087   358,201   333,141   315,776   302,489  












1,026,384   991,261  
OH  834,199   647,701   562,766   514,662   480,854   448,143   417,414   395,557   384,196  
PA  858,152   716,004   619,130   570,305   524,869   492,694   461,512   442,112   424,268  
TX  1,225,367   918,880   765,498   680,373   612,946   556,070   522,495   487,792   454,521  
























Supplementary Table 3: Eligible Sample by State 
Eligibility criteria 
 ≥18 and <65 years old 
 No private supplemental insurance 
 No Medicare co-insurance 
 Enrolled for complete calendar year 
 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 
AL  114,545   129,090   118,826  111266 99272 62824 53017 52497 50530 




1,384,836  1109272 962494 841458 757060 700581 657605 
CO  38,127   39,236   33,329  26334 26172 22706 21169 20481 20652 
FL  332,870  0  0    0 0 0 1 0 0 
GA  123,383   121,879   106,268  97452 88209 76313 68428 64921 63709 
IL  255,548   238,859   206,394  190761 178804 160527 148007 195614 188476 
MA  265,878   243,866   181,699  166935 157453 146958 136540 130089 129114 
MD  133,645   127,275   97,380  82368 71282 57965 48991 46619 52846 
NC  144,107   147,440   125,934  106883 95663 90181 81878 78460 77843 
NY  633,017   713,667   604,489  541429 511598 466164 424646 405124 407551 
OH  242,253   253,249   224,916  207868 194513 176401 154926 153412 155236 
PA  284,813   274,853   238,170  219289 206447 188253 175931 164882 160874 
TX  203,779   197,693   157,143  132080 118827 105743 101038 98412 93621 
WA  108,562   99,414   82,295  73274 64081 55659 47278 42701 45059 
Total 
               
4,561,139  
                
4,345,892  
                
3,561,679  
                
3,065,211  
                
2,774,815  
                
2,451,152  
                
2,218,910  
                
2,153,793  




Supplementary Table 4: Drug categories for non-opioid analgesics 
Proportion of all prescribed non-opioid analgesics included in the analysis by drug type. 




2001 49.00 14.11 21.63 15.26 
2002 47.78 14.22 22.90 15.10 
2003 46.28 14.53 24.33 14.86 
2004 45.77 14.63 25.17 14.43 
2005 44.59 14.90 25.58 14.93 
2006 42.77 15.08 27.01 15.13 
2007 41.69 14.75 28.28 15.28 
2008 40.83 14.94 29.13 15.10 












Background.  Prescription opioid use is greater among people living with HIV (PLWH), yet 
little is known about the prevalence of specific types of high-risk use among these 
individuals. 
 
Methods. We analyzed clinical and demographic data from the HIV Research Network 
(HIVRN) and opioid prescribing data from Medicaid claims for non-cancer patients seeking 
HIV treatment at four urban clinics between 2006-2010. HIVRN patients were included in 
the analytic sample if they received at least one incident opioid prescription. We examined 
four measures of high-risk opioid use: 1) high daily dosage; 2) early refills; 3) overlapping 
prescriptions; and 4) multiple opioid prescribers.  
 
Results. Of 4,553 eligible PLWH, 1,794 (39.4%) received at least one incident opioid 
prescription during follow-up. The sample was 62% male and 62% African American with 
a median age of 44.5 years. High-risk opioid use occurred among 33% of incident opioid 
users (high daily dosage: 12.7%; early refills: 17.9%; overlapping prescriptions: 17.1%; 
multiple prescribers: 21.0%). About half of the cumulative incidence of high-risk use 
occurred within the first year of receiving an opioid prescription. After adjusting for study 
site and nadir CD4, the hazard of high-risk use was greater among patients with IDU as an 
HIV risk factor (HR=1.54, CI 1.25-1.91), non-Hispanic whites (HR=1.44, CI 1.09-1.90), 
 63 
patients age 35-45 years (HR=2.07, CI 1.45-2.94) and patients who were not virally 
suppressed (HR=0.80, 0.66-0.99).  
 
Conclusions. High-risk opioid use was common among PLWH. Risk assessments and 
counseling on the proper use of opioids is especially important within the first year of 
receiving an opioid prescription.  
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Introduction 
Opioid use and opioid misuse have increased dramatically over the past two 
decades1–9. Drug overdose is now the leading cause of accidental death in the United States, 
with unintentional poisoning surpassing motor vehicle accidents as the leading cause of 
unintentional injury deaths in 201110. Nearly 60% of overdose deaths in the United States 
involve an opioid1, leading to a concerted effort by care providers across the country to 
carefully monitor the use of prescription opioids11–13. 
Growing concern surrounding the increase of opioid use disorders has led to 
attempts to identify precursors to opioid misuse, with the intent of allowing health 
providers the opportunity to intervene before patients experience adverse consequences. 
Some such attempts include identifying patterns of high-risk use, such as the use of 
multiple of prescribers and/or pharmacies (“opioid shopping”), receiving overlapping 
opioid prescriptions, and high daily dosage. These use patterns have been used in both 
research and clinical settings to identify possible or probable opioid use disorders9,14–20.  
While it is not possible to determine whether an individual is misusing opioids based on 
utilization patterns alone, a large body of evidence suggests that individuals with high-risk 
use patterns are at higher risk of injury or death14–18,20–24.  
One particularly vulnerable population at risk for opioid use disorders is people 
living with HIV (PLWH). HIV-associated neuropathy and antiretroviral therapy toxicities 
lead to a high prevalence of chronic pain among PLWH25–29. In addition, the prevalence of 
opioid use disorders is higher among PLWH than in the general population and may 
increase morbidity and mortality30–32.  In this study, we characterized utilization patterns 
of high-risk opioid use among PLWH and identified risk factors for high-risk opioid use.  
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Methods 
We based our assessment of high-risk opioid use on four criteria: 1) daily dosage, 2) 
overlapping prescriptions, 3) multiple prescribers, and 4) early refills. These criteria have 
been validated in prior research as a means to identify potential misuse14–18,20–24 and/or 
have been recommended by clinical experts as suggestive of high-risk opioid use. A key 
assumption of this analysis is that individuals who receive opioid prescriptions in patterns 
that meet any of these four criteria are either currently misusing opioids or are at high risk 
for opioid misuse. The term “high-risk use” will be used throughout this paper, as we are 
unable to discern whether these patterns result in abuse, addiction, dependence, and/or 
diversion; instead, these patterns indicate a high likelihood of current or potential opioid 
misuse.  
Study sample 
We analyzed data from two sources: Medicaid pharmaceutical claims and the HIV 
Research Network (HIVRN). The HIVRN contains observational, longitudinal data on 
cohorts of PLWH enrolled in care at both community and university-based clinics33. The 
HIVRN assembles data from its network of HIV care centers for the purposes of conducting 
research designed to improve accessibility, quality, and safety of healthcare services 
available to PLWH33. We used the combination of Medicaid and HIVRN data to identify 
patients who received opioid prescriptions, to describe their utilization patterns, and to 
characterize individuals meeting high-risk use criteria. 
We drew the study sample from a subset of the HIVRN cohort that linked their study 
participants’ records to the Medicaid database, allowing us to examine comprehensive 
pharmaceutical claims from Medicaid and clinical, behavioral, and social characteristics 
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from HIVRN. Investigators from urban health centers in Massachusetts, Maryland, and New 
York initiated and executed this individual-level data linkage as follows: 6,892 patient IDs 
from HIVRN were sent to CMS and 6,196 of these IDs were matched to the Medicaid 
database based on social security numbers, representing a total of 25,788 person-years34. 
Only patients with data from both sources were eligible for inclusion in our analytic 
sample. Patients age 18-65 were included in the study sample if they received at least one 
oral analgesic prescription at any time during study follow up (January 1, 2006 to 
December 31, 2010). Supplementary Table 5 summarizes the NDCs used to identify opioid 
prescriptions.  
Exclusion criteria and description of final sample 
The outcome definitions for this analysis required complete capture of all 
prescription claims. Therefore, we excluded patient-years for which the patient was also 
enrolled in either Medicare or private insurance at any time during the calendar year, as 
claims covered by supplemental insurance do not appear in the Medicaid claims file.  
Further, we included patient-years in the analysis only if they were continuous. If patients 
had a gap-year (i.e. enrolled in one year, not the next, and re-enrolled in a subsequent 
year), years subsequent to the gap were excluded from the analysis. 
Additionally, we excluded, on a state-by-state basis, Medicaid fee-for-service or 
comprehensive managed care plans if they incompletely captured prescription claims as 
determined by data exploration within our sample and evidence from prior literature 35. 
Following an analysis of the completeness and comparability of comprehensive managed 
care claims versus fee-for-service claims (Supplementary Table 6), we excluded patients on 
fee-for-service plans in Maryland and patients on comprehensive managed care plans in 
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Massachusetts. Patients from any state who were classified both as “fee-for-service only” 
and “comprehensive managed care” within the same year or as neither fee-for-service nor 
comprehensive managed care were also excluded from the analysis.  
Finally, we excluded patient-years for the following reasons: 1) patient was younger 
than 18 years or older than 65 years; 2) patient was transgender (excluded because the 
small sample size of <1% precluded an analysis of transgender patients); 3) patient had a 
non-benign cancer diagnosis (excluded to remain consistent with prior opioid studies; 
cancer patients are treated for pain under extenuating circumstances28,31,36,37); 4) patient 
was enrolled in Medicaid for <90 days; 5) patient resided in a state other than 
Massachusetts, Maryland, or New York; 6) there was a discrepancy in age (>5 years) or sex 
between Medicaid and HIVRN; 7) patient had >1 record or >365 eligible days for the 
calendar year; 8) patient was a prevalent opioid user, determined using a 6-month washout 
period.  Figure 11 shows the number excluded for each reason.  
High-risk opioid use 
We based our assessment of high-risk opioid use on four criteria: 1) daily dosage, 2) 
overlapping prescriptions, 3) multiple prescribers, and 4) early refills. We ascertained 
high-risk opioid use using Medicaid pharmacy claims. We based the first outcome, high 
daily dosage, on a standardized measure for daily dosage: morphine milligram equivalents 
(MME). The daily dosage and number of days dispensed for each opioid prescription claim 
were used to determine the MME that a patient received each day. Recommendations vary 
for defining the cutoff for overuse, ranging from 80 to 200 MME 4,38. For our purposes, we 
defined high-risk use as receiving a total daily dosage over 100 MME/day for at least 30 
consecutive days. 
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We defined the second criterion for high-risk use, overlapping prescriptions, as 
having at least one day with more than one opioid prescription from the same Drug 
Enforcement Agency (DEA) class, with DEA class categorized as1) long acting, 2) short 
acting non-Schedule II (i.e. codeine, tramadol), or 3) short acting Schedule II (i.e. 
hydrocodone, oxycodone). To ensure the drugs were not overlapping due to an early refill, 
we required that the overlapping prescriptions were either a different dosage or a different 
drug.  
Each Medicaid prescription claim includes a unique identification number for the 
prescribing physician. We used this information to identify individuals who sought opioids 
from multiple providers within a 90-day period. All individuals who received an opioid 
prescription at least three distinct prescribers within a 90-day period were considered 
high-risk opioid users by our third criterion. 
The timing of the opioid prescription refill defined the final criterion for high-risk 
opioid use. All prescription claims include the duration of the supply (i.e. 30-day supply) 
and the date that the prescription was filled. We calculated the number days early an 
individual filled a prescription and defined refill pickups as early if the individual refilled 
their prescription when at least 25% of the existing prescription remained. 
We examined modified definitions in the sensitivity analyses discussed below.  
Explanatory variables 
Exposures of interest were collected as part of the HIVRN study protocol, through 
medical record chart abstraction (age, sex, race, and study site) or site-specific lab uploads 
processed by HIVRN (nadir CD4 and HIV RNA). We defined baseline viral suppression as 
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HIV RNA <200 copies/ml, determined using the closest available HIV RNA measurement 
within one year of baseline. 
We identified comorbidities (and one exclusion criterion) using diagnosis codes 
from the HIVRN database. Diagnoses of interest included: depression39 and chronic pain40, 
as these are diagnoses found to be associated with high-risk opioid use in prior literature 
and cancer, as this was an exclusion criterion28,31,36,37. We assessed cancer at any point 
during follow-up, while we assessed depression and chronic pain prior to study baseline 
(i.e. prior to the patient’s first opioid prescription). 
Patients were considered to have cancer, and therefore excluded from the analysis, 
if they had two or more claims with ICD-9 codes for a non-benign cancer diagnosis listed in 
Supplementary Table 7. The case definition for depression was informed by a 2014 
systematic review39; the final definition was chosen based on a consideration of sensitivity, 
specificity, and the source of data available (ICD-9 codes only). For the purposes of this 
analysis, patients with one or more diagnoses from the list of “depression” diagnosis codes 
in Supplementary Table 7 were considered to have depression. This algorithm has a 
sensitivity of 32.9% and a specificity of 99.5%. The definition for chronic pain was 
motivated by a 2013 paper by Tian et al.40. Any patient with at least one diagnosis from the 
list of comprehensive pain diagnosis in Supplementary Table 7 was considered to have 
chronic pain.  
Current illicit drug use was not captured directly in either the Medicaid claims or 
the HIVRN data. As a surrogate marker for illicit drug use, we examined HIV acquisition 
risk factor to identify patients with a history of injection drug use (IDU). We classified 
patients with an HIV risk factor of “injection drug use”, as recorded in the HIVRN database, 
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as having a history of illicit drug use (we classified patients with multiple HIV risk factors 
as IDU if one of the recorded risk factors was “injection drug use”). 
Statistical methods 
Our primary outcomes were: 1) binary indicator variables for each of the four 
definitions of high-risk opioid use and 2) a composite binary indicator variable for any 
high-risk opioid use pattern. Given that the four definitions of high-risk opioid use are not 
mutually exclusive, we first assessed the proportion of patients who ever experienced each 
of the four high-risk use behaviors, determined the patterns of overlap between the four 
behaviors, and calculated their incidence rates. Then we estimated the time to the first 
indication of any high-risk opioid use and determined characteristics associated with high-
risk opioid use. As sensitivity analyses, we examined recurrences of early refills and a 
modified definition of overlapping prescriptions. Finally, we explored the association 
between high-risk use and the occurrence of emergency department visits. 
Time-to-event analysis 
We conducted a time-to-event analysis to determine the time to any high-risk opioid 
use among the study sample. The primary outcome for the time-to-event analysis was a 
composite outcome defined as any of the four high-risk opioid use behaviors. The time 
origin for each individual was the date of the first opioid prescription, and the endpoint of 
interest was the first date at which there was evidence for high-risk opioid use. Patients 
were censored on the first of either: 1) date of death, 2) last day of Medicaid coverage, or 3) 
December 31, 2010. 
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 We estimated the incidence rate and median time to first occurrence of high-risk 
opioid use. Then, because the time-to-event analysis followed patients only until their first 
high-risk use behavior, we also examined incidence rate of subsequent high-risk use 
behaviors. Finally, we fit a Cox proportional hazards model to estimate the association 
between high-risk use and our hypothesized risk factors, including IDU, depression, 
chronic pain, age, sex, race, nadir CD4, and baseline HIV viral suppression. 
Sensitivity analyses 
Unlike the indicators for multiple prescribers and overlapping prescriptions, which 
both require, by definition, the occurrence of a behavior more than once, the early refills 
indicator does not incorporate recurrence into its case definition. Therefore, as a sensitivity 
analysis, we calculated the proportion of patients who sought early refills repeatedly and 
estimated the time to first event, time to second event, and time to third event. Among 
those with at least one early refill, we estimated the difference in 1-year restricted mean 
survival times to describe the time between first and second events and the time between 
the second and third events. 
To evaluate the potential impact of misclassifying high-risk use in the scenario 
where a single provider prescribed multiple prescriptions to identify the correct dosage for 
an opioid-naïve patient, we conducted a sensitivity analysis whereby the overlapping 
prescriptions criterion was met only if distinct providers wrote the prescriptions. We used 
the revised definition to re-calculate the incidence rate of overlapping prescriptions and to 
re-define the composite outcome used in the survival analysis.  
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Association with emergency department visits 
 To explore consequences of high-risk opioid use, we examined the association 
between high-risk opioid use and emergency department visits. This exploratory analysis 
was based on the assumption that non-opioid related emergency department visits were 
approximately equal at baseline between patients with high-risk opioid use and those 
without high-risk use. Under this assumption, an increase in emergency department visits 
among patients with high-risk opioid use could be attributed to their opioid use. 
 We modeled the number of emergency department visits per year longitudinally 
using a generalized linear model with a Poisson distribution, fit using generalized 
estimating equations with an autoregressive correlation structure to account for within-
patient correlation. We included a time-varying covariate for the presence of any high-risk 
opioid use behavior. Because emergency department visits were measured annually (total 
number per year, no dates specified), we could not precisely determine whether the visit 
occurred before or after the onset of the high-risk utilization behavior. As a best estimate, 
we attributed high-risk use behaviors within the first half of the year to emergency 
departments within that year; high-risk use behaviors in the second half of the year were 
attributed to emergency department visits in the next year. 
Results 
 Our sample included 1,794 PLWH with at least one incident opioid prescription 
between 2006-2010, which represents 39.4% of the 4,553 patients meeting the eligibility 
criteria (31.4% of eligible patients did not receive any opioid prescriptions during follow-
up and 29.2% were prevalent opioid users). The final analytic sample was 61.7% male and 
the median age at study baseline was 44.5 years (interquartile range 38-50 years). Nearly 
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two-thirds (62.0%) were African American. Approximately one third (31.3%) of patients 
had an HIV acquisition risk factor of IDU, 31.1% had a diagnosis of depression prior to 
baseline, and 19.3% had a diagnosis of chronic pain prior to baseline. Most patients were 
from New York (62.8%) and Maryland (30.8%), while 6.5% were from Massachusetts 
(Table 9). 
Among the 1,794 patients who received at least one incident opioid prescription, the 
median number of opioid prescriptions per patient per year was 2 (IQR: 1-6). The median 
daily dosage was 39.3 MME (IQR: 22.5-80; mean: 71.1). Slightly more than half of all opioid 
prescriptions (54.9%) were short-acting Schedule II, 23.2% were long acting, and 21.9% 
were short-acting non-schedule II. The most commonly prescribed opioid was short-acting 
oxycodone (43.5% of all prescription opioids) (Table 9). 
Incidence of high-risk use 
Approximately one third (32.8%) of patients ever met one of the four high-risk use 
criteria. The most common high-risk use behavior was multiple prescribers, with 21.0% of 
patients ever receiving opioid prescriptions from at least 3 distinct prescribers in 90 days, 
for an incidence rate (IR) of 10.7 per 100 person-years (PY). Eighteen percent of patients 
ever refilled a prescription when at least 25% of the prior prescription remained (IR=9.1 
per 100 PY); 17.1% ever had overlapping prescriptions (IR=8.6 per 100 PY); and 12.7% 
ever had a high daily dosage over 100 MME for 30 or more consecutive days (IR=6.1 per 
100 PY) (Table 10).  
Figure 12 depicts the overlap between the four use patterns, showing that 75 (4.2%) 
patients met criteria for all four high-risk behaviors while 1,205 (67.2%) did not meet 
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criteria for any behavior. 232 (12.9%), 145 (8.1%) and 137 (7.6%) met criteria for one, two 
and three outcomes, respectively.  
Of the 589 individuals who met high-risk use criteria, 357 met criteria for more than 
one high-risk use pattern. Table 11 depicts incidence rates of subsequent high-risk patterns 
among individuals who fulfilled multiple criteria for high-risk use. For example, among 95 
patients who first met criteria for high daily dosage, the incidence rate of subsequently 
meeting criteria for another pattern ranged from 16.1 per 100 PY (overlapping 
prescriptions) to 25.1 per 100 PY (multiple prescribers).  
Time-to-event analysis 
The incidence rate for any high-risk opioid use behavior was 20.0 events per 100 
person-years. After 1 year of follow-up, the cumulative incidence was 26% and at 4 years of 
follow-up the cumulative incidence was 45%. Figure 13 displays the cumulative incidence 
function for the composite high-risk opioid use outcome; the solid curve shows the total 
cumulative incidence of any high-risk use and the dashed lines depict the cumulative 
incidence that each of the four high-risk use patterns contribute individually. 
Patients with complete covariate data (n=1,412) were included in the multivariable 
regression analysis, representing 422 events. The 382 patients with missing data were 
excluded due to missing HIV viral load or CD4 measurements; the incidence rate of high-
risk opioid use was not differential among patients excluded due to missing lab values. In a 
multivariable adjusted Cox regression model, IDU as an HIV acquisition risk factor, age, 
race, and baseline viral suppression were associated with high-risk opioid use (Table 12). 
The adjusted hazard ratio (aHR) for high-risk opioid use was 1.54 (95% CI 1.25-
1.91) comparing patients with IDU as an HIV acquisition risk factor to those with a non-IDU 
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related risk factor (i.e. men who have sex with men, high-risk heterosexuals). Patients who 
were age 35-45 at study baseline had twice the hazard for high-risk use compared to 
patients less than 35 at study baseline (aHR=2.07, 95% CI 1.45-2.94). Patients older than 
45 also had an increased hazard for high-risk use compared to patients in the lowest age 
category, but the increased hazard decreased with each increasing age category (aHR=1.88, 
95% CI 1.31-2.69 for patients age 45-55 at baseline; aHR=1.44, 95% CI 0.92-2.26 for 
patients age 55-65 at baseline). 
Patients who were virally suppressed showed a significantly lower hazard for high-
risk opioid use (aHR=0.80, 95% CI 0.66-0.99). Non-Hispanic whites had a higher risk for 
high-risk opioid use compared to African Americans (aHR=1.44, 95% CI 1.09-1.90), while 
Hispanics and patients of unknown or other races demonstrated a non-significant 
decreased hazard for high-risk opioid use compared to African Americans. 
Non-significant associations were found with respect to sex and chronic pain. Males 
demonstrated a non-significant increased hazard of high-risk opioid use (aHR=1.18, 95% 
CI 0.97-1.45). Having a diagnosis chronic pain prior to one’s first opioid prescription was 
associated with a non-significant increased hazard for high-risk opioid use (aHR=1.17, 95% 
CI 0.92-1.50).  
Recurrence of early refills: a sensitivity analysis 
Among patients who met early refill criteria (n=322), the mean number of early 
refills over the follow-up period was 2.7 (median 2, IQR 1-3). In total, 150 patients (8.4%) 
refilled their opioid prescription only once, 59 (3.3%) refilled early exactly twice, 41 
(2.3%) refilled early exactly three times, and 72 (4.0%) refilled early four or more times, up 
to a maximum of 17 times over the duration of follow-up. The incidence rates for first early 
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refill, second early refill, and third early refills were 9.1 per 100 person-years, 4.5 per 100 
person-years, and 2.8 per 100 person-years, respectively. The top panel of Figure 14 
displays the Kaplan-Meier survival curves for time to first, second, and third early refill. 
The bottom panel of Figure 14 shows the time from the first (or second) early refill until 
the subsequent (either second or third) early refill. 
 Among the full sample of 1,794 patients, the restricted mean survival time (RMST) 
up to 4.8 years of follow-up for the first early refill was 3.9 years (95% CI 3.8-4.0 years) and 
the RMST up to one year of follow-up was 0.73 years (95% CI 0.70-0.76 years).  That is, the 
expected time to early refill is 0.73 years during the first year of follow-up. When 
examining the time between the first and second early refills, the RMST up to one year was 
0.41 years (95% CI 0.36-0.46 years). Therefore, comparing the RMST for first as compared 
to second early refill over a 1-year period, it took patients about 0.32 years (or 16.6 weeks) 
longer to reach their first early refill than their second. The comparable 1-year RMST for 
the time to third early refill following the date of the second early refill was 0.36 years 
(95% CI 0.30-0.42 years). 
Overlapping prescriptions: a sensitivity analysis 
 When we redefined overlapping prescriptions such that the overlapping 
prescription criteria was only satisfied when distinct prescribers provide the prescriptions, 
the incidence rate dropped to 7.1 per 100 person years (from 8.6 per 100 person-years). 
When restricting the definition further, requiring the overlapping prescriptions not only to 
come from distinct providers but also to be distinct drugs, the incidence rate decreased to 
5.7 per 100 person-years. Because overlapping prescriptions only occasionally defined the 
endpoint of interest in the composite outcome survival analysis, the overall incidence rate 
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for high-risk opioid use remained fairly unchanged: the modified definitions of overlapping 
prescriptions reduced the incidence rate for high-risk opioid use from 20.0 per 100 person-
years to 19.7 and 19.1 per 100 person-years, respectively. 
Association with emergency department visits 
 Emergency department visits were generally infrequent, with a mean number of 
emergency department visits per year of 0.71 (median=0 and IQR=0-1). In a Poisson model 
adjusted for age, sex, race, injection drug use, nadir CD4, and baseline viral suppression, we 
found a slight increase in emergency department visits among patients with high-risk 
opioid utilization compared to those without, but this increase was not statistically 
significant (aRR=1.20, 95% CI 0.98-1.50).  
Discussion 
We conducted time-to-event analysis among PLWH receiving an incident opioid 
prescription to estimate the incidence of high-risk opioid use and determine factors 
associated with high-risk use. High-risk opioid use was common among these subjects, 
with 33% of patients exhibiting at least one of the four high-risk use outcomes. Of the four 
high-risk use metrics we studied, the incidence rate was highest for multiple prescribers, 
followed by early refills and then overlapping prescriptions. These results are important 
because while chronic non-cancer pain is common among PLWH, relatively little is known 
regarding patterns of high-risk opioid use among this population. Our findings underscore 
the importance of prescription drug monitoring programs to track prescribing patterns, 
including prescriptions dispensed by other providers. 
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The four distinct high-risk use patterns do not occur in isolation. Prior literature has 
demonstrated an association between each of these four high-risk use behaviors 
independently and adverse consequences such as opioid use disorders or opioid 
diversion14–18,20–23, but few studies have compared the validity of the metrics to one 
another. Though the goal of this paper was not to directly compare the four distinct high-
risk use patterns, we did find that the incidence rate of each pattern increased substantially 
if an individual had already met criteria for one of the other high-risk use patterns, 
suggesting that these behaviors are interrelated.  
Of note, approximately half of the total cumulative incidence of high-risk use 
occurred within the first year after a patient received an incident opioid prescription. The 
first year of opioid use likely represents a critical period, as addiction and development of 
opioid use disorders often occur early in treatment41. Because of the startling incidence of 
high-risk opioid use within the first year, it is especially important for providers to ensure 
careful and dedicated opioid counseling to patients receiving new opioid prescriptions. 
Opioid risk assessment screenings such as the Brief Risk Interview, which has been found 
effective in predicting aberrant opioid use42, may be useful among high-risk populations.  
Similar to research in HIV-negative populations, we found a higher hazard for high-
risk opioid use among patients with a history of IDU. We also found an increased hazard for 
high-risk opioid use among patients age 35-55 years (but not 55-65) compared to patients 
age 18-35, among men compared to women, and among non-Hispanic whites compared to 
African Americans. Interestingly, we did not find an association between depression and 
high-risk opioid use, which is in contrast to previous literature17,18,43,44. The use of ICD-9 
diagnostic codes to define depression may have been an imperfect identifier, as psychiatric 
 79 
conditions that were undiagnosed and/or did not appear in ICD-9 claims could not be 
examined. 
Approximately half of all patients with at least one early refill had recurrent early 
refills. Over a one-year period, patients who had at least one early refill spent an average of 
0.73 years (approximately 38 weeks) before seeking their first early refill. The one-year 
RMST between the first and second refill was slightly shorter (approximately 21 weeks), 
and the one-year RMST between the second and third early refills decreased even more to 
approximately 19 weeks. This pattern indicates that while early refills become habitual 
among only some patients, those who engage in early refill behavior numerous times may 
be of particular concern. 
Modifying the definition of overlapping prescriptions to exclude overlapping 
prescriptions that were prescribed by the same provider reduced the incidence rate by 
nearly 20%. While the revised definition did not impact the incidence of the composite 
high-risk use outcome, investigators should be cautious when using overlapping 
prescriptions to flag possible or probable misuse; overlapping prescriptions, especially if 
they are prescribed to opioid-naïve patients by a single provider, may be an artifact of dose 
titration rather than opioid misuse. 
We chose to use a sensitive definition for overlapping prescriptions by requiring 
only a one-day overlap. More stringent criteria could be used; however, we found that 90% 
of patients who had an overlap of at least one day also had an overlap of at least 4 days, 
with a median number of overlapping days of 36. Therefore, we used the conservative 
definition for overlapping prescriptions to ensure capture of all instances of overlapping 
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prescriptions. Even with our sensitive definition, overlapping prescriptions was only the 
third most common of the four behaviors examined. 
High-risk opioid use is a difficult behavior to measure, as the level of opioid 
consumption that is inappropriate may vary by individual. Our assessment of high-risk use 
from prescription claims therefore acted as a proxy for misuse, which is not a perfect 
surrogate. We estimated the association between combinations of the high-risk utilization 
metrics and change in annual emergency department visits to assess face validity of the 
measures but found no significant associations. The null findings are likely due to the non-
specific nature and relative rarity of emergency department visits. Outcomes more directly 
related to high-risk opioid use, such as cause-specific mortality, overdose events, or 
incident opioid dependence and/or addiction diagnoses, would provide a more optimal 
means for validation.  
Because we defined the outcome for this study using prescription claims records as 
a surrogate marker for opioid misuse, the increased hazard for high-risk use could be due 
in part to patients having more severe pain or receiving treatment from providers who 
tend to prescribe more opioids, thereby increasing the likelihood of meeting high-risk use 
criteria. One must be cautious in interpreting these results: we identified patients at 
highest risk for obtaining opioid prescriptions in patterns that are predictive of high-risk 
use, not necessarily patients who are currently misusing opioids.  
Our study had some limitations. We were unable to determine whether patients 
seeking opioid from multiple prescribers did so from two or more providers within the 
same clinic, a pattern that may reflect a trend in practice patterns within a clinic rather 
than a patient’s high-risk use behavior. Because we analyzed claims data, we only know 
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whether drugs were dispensed, but not if or how the patient took the drug. Similarly, we 
were unable to study adverse consequences of high-risk opioid use such as addiction, 
overdose, or diversion. Analyzing data only from patients who were enrolled in Medicaid 
restricted the generalizability of the study; however, Medicaid is the largest insurer of 
PLWH, covering approximately 40% of nonelderly PLWH in care45. Finally, we analyzed 
prescriptions claims from 2006-2010, which represents an era slightly before widespread 
adoption of recent opioid prescribing recommendations.   
Despite these limitations, our study had several strengths. The combination of two 
distinct data sources allowed us to address some challenges of using Medicaid data alone, 
including the inability of studies using claims data to examine clinical outcomes (i.e. CD4 
and HIV RNA lab values) and demographic data that are often missing and/or inaccurate in 
claims data (i.e. race/ethnicity). Additionally, the four distinct study sites allowed us to 
examine utilization practices that may vary by location; the addition of even more study 
sites could add further value to future research. Finally, the analysis of the overlap between 
four distinct utilization behaviors provided further insight into patterns of opioid use that 
are most predictive of harmful outcomes.  
This study extends existing knowledge about characteristics associated with high-
risk opioid use to PLWH and expands on prior studies examining utilization patterns 
indicative of opioid misuse. We simultaneously analyzed previously described metrics for 
doctor shopping, overlapping prescriptions, high daily dosage, and early refills to 
determine the incidence rates of the behaviors both separately and combined. Finally, we 
described characteristics associated with high-risk use among PLWH. Our results can be 
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Table 9: Descriptive statistics 
N=1,794 patients receiving at least one incident opioid prescription 
Patient Characteristics, N (%) 

























IDU as HIV risk factor 561 (31.3) 
Depression prior to baseline 558 (31.1) 
Chronic pain prior to baseline 346 (19.3) 
Nadir CD4, median (IQR) 281 (130, 447) 
Virally suppressed at baseline 572 (40.4) 
Duration of follow-up in years, median (IQR) 2.2 (1.1, 3.5) 
Total person-years of follow-up 4,120.34 
Died during follow-up 143 (8.0) 
Prescription Characteristics, N (%) 
Total number of opioid prescriptions 17,896 
Annual opioid prescriptions per person, median (IQR) 2 (1, 6) 
Daily dosage in morphine milligram equivalents, median (IQR) 39.3 (22.5, 80) 
Drug Enforcement Agency Class 
Long acting 
Short acting non-Schedule II 








Table 10: Summary statistics for each high-risk use behavior 
N=1,794 patients receiving at least one incident opioid prescription 
 
 Number (%) of individuals Incidence rate per 100 person-years 
High daily dosage 228 (12.7) 6.1 
Early refills 322 (17.9) 9.1 
Overlapping prescriptions 307 (17.1) 8.6 




Table 11: Incidence rate of subsequent high-risk opioid use patterns among patients 
who met multiple criteria for high-risk use, by first-occurring high-risk use pattern 
N=589 patients with at least one high-risk use event 
 Incidence Rate (per 100 person-years) of Additional High-risk 



















-- 21.6 16.1 25.1 
Early refills 
(N=156) 












Table 12: Multivariable adjusted Cox regression model for time to first high-risk 
opioid use behavior 
N=1,412 patients with complete covariate data; 448 events; model adjusted for study site 
 HR (95% CI) p-value 
Age 
18 to <35 
35 to <45 
45 to <55 











Male Sex  1.18 (0.97-1.45) 0.100 
Race 
African American 













IDU as HIV risk factor 1.54 (1.25-1.91) <0.001 
Depression diagnosis 1.01 (0.82-1.25) 0.896 
Chronic pain diagnosis 1.17 (0.92-1.49) 0.192 
Nadir CD4 
<50 
50 to <200 
200 to <350 

























6,196 patients in 
Medicaid-HIVRN 
linkage 
137 from states other 
than MA, MD, and NY 
6,059 










86 eligible for <90 
or >365 (or >366) days 
4,921 
2 with >1 record per 
year 
4,919 
366 cancer diagnosis 
1,431 with no opioid 
prescription 
4,553 
1,328 with prevalent 
opioid use 
3,122 
1,794 final study 
sample 
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Figure 13: Cumulative incidence of high-risk opioid use  
The solid curve (the sum of Regions A through D) depicts the total cumulative incidence of 
any high-risk use behavior. The dashed lines depict the portion of the total cumulative 
incidence that each of the four high-risk use patterns contributes. Region A depicts the 
cumulative incidence contributed by high-daily dosage. Region B depicts the cumulative 
incidence contributed by overlapping prescriptions. Region C depicts the cumulative 
incidence contributed by early refills. Region D depicts the cumulative incidence 














Supplementary Table 5: Summary of pre-defined NDCs used to identify opioid 
analgesics 
Number of unique NDCs used to define opioid analgesics. Actual NDCs not listed. 
Drug Type Total number of NDCs included 
Hydrocodone 4354 
Codeine 1849 
Oxycodone SA 1466 
Propoxyphene 1385 
Tramadol 1094 
Morphine LA 681 
Morphine SA 618 
Hydromorphone 456 
Oxycodone LA 312 
Fentanyl LA 209 
Methadone 206 
Fentanyl SA 144 
Pentazocine 137 














Supplementary Table 6: Exploration of two types of Medicaid plans 
 Patients with ≥1 
prescription (any) 
Patients with ≥1 
opioid prescription 
Fee-for-service plans (N=3,344) 
State of residence 
Massachusetts (n=422) 
Maryland (n=283) 


























36 (15, 61) 
46 (14, 103) 
66 (34, 107) 
 
2 (1, 7) 
4 (2, 12.5) 
5 (2, 12) 
Comprehensive managed care plans (N=3,133) 
State of residence 
Massachusetts (n=52) 
Maryland (n=1,542) 


























20.5 (10, 38.5) 
41 (16, 75) 
52 (23, 95) 
 
5 (1, 9) 
3 (1, 10) 




Supplementary Table 7: Exposure definitions 
Diagnosis ICD-9 Codes used for Case Definition 
Cancer 140-239 
Depression  296.20 296.21 296.22 296.23 296.24 296.25 296.30 296.31 296.32 296.33 296.34 
296.35 300.4 311 296.5 296.6 296.82 296.90 309.0 309.1 309.28 
Chronic pain  338.2 338.21 338.22 338.28 338.29 338.4 307.8 307.89 338 719.41 719.49 
719.45 719.46 719.47 720 720.2 720.9 721 721.1 721.2 721.3 721.41 721.42 
721.6 721.8 721.9 721.91 722 722.1 722.11 722.2 722.3 722.31 722.32 722.39 
722.4 722.51 722.52 722.6 722.7 722.71 722.73 722.8 722.81 722.82 722.83 
722.9 722.91 722.92 722.93 723 723.1 723.3 723.4 723.5 723.6 723.7 723.8 
723.9 724 724.01 724.02 724.09 724.1 724.2 724.3 724.4 724.5 724.6 724.7 






Chapter 4: Estimating the prevalence of opioid diversion using 




Background.  The prevalence of opioid diversion is difficult to measure because of social 
desirability bias and because of this there is a dearth of information on diversion. Given the 
increased prevalence of opioid use among people living with HIV (PLWH), the risk for 
opioid diversion is concerning in this population. We applied a method designed to provide 
a more accurate estimate of sensitive behaviors to assess the prevalence of opioid 
diversion among PLWH. 
 
Methods. Between October of 2016 and June of 2017, we randomized patients from the 
Johns Hopkins HIV Clinical Cohort who had ever received an opioid prescription to answer 
either a direct or indirect question about opioid diversion. For the indirect question, we 
applied the crosswise method. We estimated the prevalence of opioid diversion under each 
method. We further estimated the prevalence of opioid diversion in subsets of the sample 
by sex, race/ethnicity, HIV risk group, illicit drug use, smoking status, depressive 
symptoms, and anxiety. 
 
Results. Of 1,158 patients screened, 541 (46.7%) reported that they had ever received an 
opioid prescription. Among these patients, 284 answered the indirect question about 
opioid diversion and 244 directly answered whether they had ever diverted opioids. The 
prevalence of opioid diversion using the indirect questioning method was 11.5% (95% CI 
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6.4%-16.6%) and the prevalence using the direct questioning method was 6.1% (95% CI 
3.5%-9.9%). Ever having used cocaine was associated with an increased prevalence of 
opioid diversion (aOR=16.3). 
 
Conclusions. The crosswise method of indirect questioning can be used to estimate the 
prevalence of opioid diversion in the absence of social desirability bias. Among our sample 
of people living with HIV, the prevalence of opioid diversion was nearly twice as high using 
the indirect questioning method compared to a direct questioning method.  
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Introduction 
Rates of opioid prescriptions have risen over the past two decades, leading to an 
increase in aberrant opioid use, drug overdose, and drug-related mortality1. Initiatives such 
as the development of prescription drug monitoring programs are designed to reduce 
overprescribing and prevent individuals from receiving too many opioids2. Nonetheless, a 
large supply of opioid prescriptions is still in circulation across the United States3. The 
dispensing of excess or unneeded opioid prescriptions opens the door for intentional or 
unintentional opioid diversion, or the unlawful transfer of an opioid prescription to an 
unintended recipient.  
Opioid diversion is particularly dangerous because it results in unmonitored 
consumption of the drugs. The National Survey on Drug Use and Health found that over 
70% of individuals who abuse prescription painkillers received the drugs through 
diversion4. Despite the high prevalence and severe negative consequences of opioid 
diversion, efforts to combat diversion in the United States have been inconsistent and 
largely ineffective4, leading to a continued problem with opioid diversion across the 
country. 
Accurate prevalence estimates for aberrant opioid use are difficult to obtain, as 
individuals hesitate to self-report behaviors such as opioid overuse or diversion that are 
stigmatized or illegal. An indirect method for estimating the prevalence of opioid misuse 
can provide a more accurate prevalence measurement and can be used to validate direct 
estimation methods. With an indirect questioning method, researchers induce a known 
amount of measurement error into the study design, which provides anonymity to the 
respondent and increases the likelihood of honest responses. This measurement error can 
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subsequently be adjusted to obtain accurate estimates for the prevalence of sensitive 
behaviors.  
In this study, we applied an indirect questioning technique to measure the 
prevalence of opioid diversion in the Johns Hopkins HIV Clinical Cohort (JHHCC). Indirect 
questioning techniques have been found to elicit more honest responses, as individuals are 
not asked to provide an answer to a sensitive question directly. We used the crosswise 
method of indirect questioning5 to estimate the prevalence of opioid diversion in the study 
population, compared the prevalence estimated through indirect questioning to the 
prevalence estimated by directly asking patients about opioid diversion, and used logistic 
regression techniques for randomized responses to identify risk factors for diversion using 
the outcome as identified through indirect questioning.  
Methods 
The JHHCC contains data on approximately 2,000 HIV-infected patients, with 
approximately 85% of them seeking all of their care within the Johns Hopkins system6. As 
part of the standard of care at the clinic, patients are asked to consent to participate in the 
clinical cohort. Consenting patients complete an automated computer-assisted self-
interview (ACASI) survey at all study visits. An ACASI is a computerized interview that the 
patient completes in private, without having to verbally disclose information directly to the 
provider. Prior research suggests that the use of ACASI software may produce more 
accurate self-reported information on sensitive subjects compared to a verbal interview7. 
All patients who provided informed consent to enter the clinical cohort were eligible to 
answer the opioid diversion questions on the ACASI. Following Institutional Review Board 
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(IRB) approval from the Johns Hopkins School of Medicine IRB, we collected data between 
October 2016 and June 2017. 
We began by asking a screening question to all patients: “Has your doctor ever given 
you a prescription narcotic such as oxycontin, oxycodone, Percocet, fentanyl, tramadol, etc. 
to treat pain?” If the patient answered no to this question, we did not provide any further 
questions about opioid diversion. Patients who answered yes to the screening question 
were randomized to answer a question about opioid diversion, either directly or indirectly. 
The direct question asked: “Have you ever given away or sold your prescription pain 
medication (such as oxycodone, Percocet, tramadol)? This includes giving the medicine to a 
family member or friend for free.”  
For the indirect question, we employed crosswise method5. The crosswise method is 
an indirect questioning technique whereby respondents simultaneously answer two 
true/false questions (one sensitive question and one non-sensitive question, the answers 
to both are unknown to the interviewer) by stating whether the answer to both questions 
is the same or different. The rationale behind this method is that because the respondent 
does not state whether the responses are true or false, the stigma associated with 
answering the sensitive question decreases and the respondent is more likely to provide an 
honest answer. 
For patients randomized to the indirect question, the ACASI presented instructions 
to consider the answer to both the sensitive and non-sensitive question simultaneously. 
The non-sensitive question was “Was your mother born in February, April or November? If 
you do not know your mother’s birthday, think of your grandmother or some other woman 
whose birthday you know.” The non-sensitive was the same as the direct response 
 104 
question above. As is standard with the crosswise method for indirect questioning the 
response options were: A) “My response is ‘No’ to both questions OR ‘Yes’ to both 
questions” or B) My response is ‘Yes’ to one of the questions and ‘No’ to the other. 
Because the required sample size for crosswise technique depends on the 
prevalence of the non-sensitive question, we chose to ask about the three months with the 
lowest proportion of birthdays. We chose three months because the prevalence of more 
than three would require too large a sample size than was feasible, and fewer than three 
months may be too specific for patients to feel their answers are truly anonymous. Based 
on historical CDC8,9 (1950 and 1955) and UN10 (1969-2014) data for all live births in the 
United States, we expected the probability of their mother being born in those three birth 
months to be 23.5%.  
We pilot tested the questions using a convenience sample by presenting the 
questions to patients and asking for verbal feedback regarding the clarity of the question. A 
research assistant was present while patients completed the ACASI and was available to 
answer questions if patients expressed confusion about the technique.  
Statistical Methods 
This study was designed to 1) estimate the prevalence of opioid diversion in the 
JHHCC and 2) to identify risk factors for opioid diversion. We applied an indirect 
questioning technique, the crosswise method, to ask study participants about opioid 
diverting behavior. This technique induces a pre-determined amount of measurement 
error, which can be corrected using the prevalence formula described by Yu et al.5:  
π̂ =
λ̂ + p − 1
2p − 1
, with p ≠ 0.5, 
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where π̂ is the probability of opioid diversion, p is the probability that the non-sensitive 
question is true, and λ̂ is the proportion of respondents indicating that the answers to the 
sensitive and non-sensitive questions are the same. We used an estimated probability 
p=0.235 and measured λ̂ from the sample data to calculate the estimated probability of 
opioid diversion in the JHHCC population. 
The variance for the prevalence estimate can be calculated as follows5: 
Var(π)̂ =
π ∗ (1 − π)
n
+
p ∗ (1 − p)
n ∗ (2p − 1)2
. 
To assess factors that may be associated with opioid diversion, we calculated the 
prevalence of diversion within subsets of the full study sample, stratified by characteristics 
we hypothesized may be associated with opioid diversion, including age, sex, mental health 
co-morbidities, and history of illicit substance use. Because of the small sample size and 
correspondingly large variance within subsets of the study sample, the stratified 
prevalence estimates were a secondary analysis. 
Finally, we used the results of indirect questioning to identify risk factors for opioid 
diversion using a multivariate generalized linear model designed for the analysis of 
randomized response outcomes. To achieve this, we used the RRreg package in R11 and 
specified that the data were collected under the crosswise model. We considered 
demographic, social, and behavioral risk factors including age, sex, race, mental health 
diagnoses, HIV risk factors, smoking, and illicit drug use. We examined odds ratios for 
relevant characteristics in a multivariate logistic regression model to identify risk factors 




 The screening question was presented to 1,176 patients, of whom 1,158 (98.5%) 
provided an answer. Of these, 541 (46.7%) responded ‘yes’ to ever having received an 
opioid prescription and were then asked to answer the opioid diversion questions. The 
sample was 61% male with a median age of 42 years (interquartile range: 35-49 years). 
The majority of patients (86%) were African American. Slightly more than half of the 
population (57%) reported an HIV acquisition risk factor of high-risk heterosexual, while 
36% reported injection drug use and 22% reported men who have sex with men (MSM). 
Nearly all patients were taking antiretroviral therapy (93%) and 92% were virally 
suppressed. About one third of patients (34%) were never smokers, 23% were former 
smokers, and 42% were current smokers. Approximately 30% of patients had at least mild 
depressive symptoms on the PHQ-8 and about 20% had at least mild anxiety on the 
Generalized Anxiety Disorder scale. Illicit drug use was common among the sample: 57% 
had ever used marijuana, 51% had ever used cocaine, 38% had ever used non-medial 
opiates, 8% had ever used amphetamines, and 17% had ever used other illicit substances. 
Table 13 reports characteristics of the study sample. 
 The majority of patients who were presented with an opioid diversion question 
provided an answer, with only 13 patients (2.4%) leaving the question blank (5 skipped the 
direct question, 5 skipped the indirect question, and for the remaining 3 missing answers 
we were unable to determine whether the patient was presented with the direct or indirect 
questions). Supplementary Table 8 summarizes the responses to all opioid diversion 
questions during the data collection period. 
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Prevalence of opioid diversion 
A total of 284 patients provided a response to the indirect question that asked 
patients to state whether their responses to the two questions presented was the same or 
different. About 70%, or 200 patients, stated that their response to both questions was the 
same and 84 (29.6%) responded that their responses to the two questions differed. Under 
the assumption that the expected probability of answering ‘yes’ to the mother’s birthday 
being in February, April, or November is 23.5% (based on CDC and UN data for the number 
of births per month in the United States8–10), the calculated probability of opioid diversion 
under the indirect questioning technique was 11.5% (95% CI 6.4%-16.6%). 
Overall, 244 patients directly answered whether they have ever diverted opioids, of 
whom 15 answered ‘yes’ for an overall probability of 6.1% (95% CI 3.5%-9.9%), indicating 
that the prevalence estimate nearly doubled under indirect questioning method. 
Secondary analyses 
In secondary analyses, the estimated prevalence of opioid diversion varied among 
sub-populations. Under the indirect questioning method, the prevalence estimate for 
women was 4.4% compared to 16.3% among men. African Americans had a smaller 
estimated prevalence (7.9%) compared to other races (25.5%). The most notable 
differences in prevalence occurred by history of illicit substance use: patients with a 
history of amphetamine use, cocaine use, and other illicit substances had prevalence 
estimates of 43.3%, 21.4%, and 28.5%, respectively, compared to prevalence estimates less 
than 7% for each of their respective counterparts. Stratified prevalence estimates using the 
direct questioning method were highest among patients with depression (12.2% vs. 4.9%), 
a history of amphetamine use (14.8% vs. 5.3%), and a history of other illicit drug use 
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(15.1% vs. 3.5%). Table 14 presents stratified prevalence estimates for subsets of the 
population under both the indirect and direct questioning methods.  
In a multivariate adjusted logistic regression model for randomized response 
outcomes, ever-use of cocaine was strongly associated with opioid diversion, with an odds 
ratio of 16.3 (Table 15). 
Discussion 
Obtaining an estimate for the prevalence of opioid diversion is an important first 
step in combating the diversion problem in the United States. To measure progress, it is 
essential to understand the scope of the problem and to establish benchmarks for 
improvement. By consistently measuring the prevalence of opioid diversion, researchers 
and practitioners can assess the success of initiatives developed to reduce diversion and 
can gauge the need for additional targeted interventions. Applying an indirect questioning 
technique such as the crosswise method is a useful way to accurately determine changes in 
the prevalence of opioid diversion in a population. 
We estimated an overall prevalence of opioid diversion of 6.1% using the direct 
questioning method and 11.5% using the indirect questioning method. Because of a paucity 
of literature on the prevalence of opioid diversion, we did not have a strong a priori 
hypothesis regarding the prevalence values; however, we did anticipate a meaningfully 
higher prevalence using the indirect questioning method. Our small, single-site study 
suggests that the crosswise method for indirect questioning does in fact provide a more 
accurate prevalence estimate for opioid diversion. We believe the estimate obtained via 
indirect questioning is a more accurate reflection of the true prevalence of opioid diversion 
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as it is not subject to social desirability bias, which is a known drawback to self-reported 
measures of sensitive behaviors. 
In our secondary analyses, we estimated the prevalence of opioid diversion among 
sub-populations; however, we did not have statistical power to determine significant 
differences between any of the strata. Similarly, we were not powered to detect statistically 
significant odds ratios in the multivariable logistic regression model. The odds ratios we 
present in our analysis should be considered explanatory; larger studies are needed to 
further assess characteristics associated with opioid diversion.  
Our study sample was composed of PLWH from a single urban clinic who are all 
engaged in care, the majority of whom have good compliance with antiretroviral therapy. 
These patients are not representative of all PLWH, particularly those who are not engaged 
in care or those from non-urban settings. The prevalence of opioid diversion is likely highly 
variable across geographic regions; results from this one study should not be generalized 
to other populations. Nonetheless, the results from this study serve as a valuable example 
of an application of the crosswise method of indirect questioning to the estimation of 
opioid diversion in an urban HIV clinic. Additional studies are needed to determine the 
prevalence of opioid diversion in other populations.  
The success of the crosswise method depends on the assumption that respondents 
understand the instructions provided; therefore, it is essential that the instructions be 
written in clear and simple language. We used prior examples from the literature to aid in 
the development of the written instructions12. Because patients did not have the option to 
provide a yes or no answer to the sensitive and non-sensitive questions, respondents who 
may not have understood the instructions were forced to consider the answer choices and 
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could revisit the instructions to determine whether to choose the “same” or “different” 
answer choice. In future studies, more sophisticated pilot testing may be beneficial to 
ensure the study population fully understands the technique. 
In addition to understanding the instructions, participants must also trust the 
method enough to provide an honest answer. Because we asked participants a sensitive 
question regarding an illegal behavior, a natural response is to lie for self-preservation. To 
minimize this, we chose to use the crosswise model, which does not have an obvious self-
protective “no” answer. Alternative methods of indirect questioning13,14 have the 
disadvantage of having a self-protective answer that participants may tend towards 
regardless of the truth. We chose to use the crosswise method for this aim in part due to its 
lack of a self-protective answer, which should help to increase the honesty of responses. 
Although indirect questioning techniques elicit more honest responses than direct 
questioning, they are also associated with an increased variance of the prevalence estimate 
and consequently require a larger sample size to achieve adequate estimates. The sample 
size is dependent on the prevalence of both the sensitive and non-sensitive question, so we 
chose a non-sensitive question with low enough prevalence that the required sample size 
was feasible, but also high enough that the respondents would still feel their responses are 
protected.  
In our study, the prevalence of the non-sensitive question was 23.5% according to 
prior literature from across the United States. However, if the prevalence of birthdays in 
our study sample differed from that of the general US population, the estimated prevalence 
of opioid diversion would be inaccurate. Supplementary Table 9 shows how the estimated 
prevalence of opioid diversion changes with various “true” prevalence measures for the 
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non-sensitive question. For example, due to a programming error 198 patients in our study 
directly answered the non-sensitive question about their mother’s birthday; 27.8% of these 
patients responded ‘yes’ (95% CI 21.7%-34.6%). Though this prevalence estimate is 
notably higher than the estimate used in our calculations, the confidence interval contains 
the value of 23.5% that was obtained from all live births in the United States. Therefore, we 
believe that the prevalence of the non-sensitive question for this analysis is accurate. 
A final challenge associated with indirect questioning is that the resulting data are in 
aggregate rather than on an individual level. Indirect questioning techniques are useful for 
measuring the overall prevalence of a sensitive behavior in a population, and this has been 
the most often cited use of the technique. However, results from indirect questioning can 
also be used as both a predictor/covariate15 and the response16 in a regression model, and 
statistical packages have been developed in both R and Stata to appropriately fit these 
models. Though we were not powered to detect statistically significant characteristics 
associated with opioid diversion in this study, we conducted a secondary analysis in order 
to provide information that may be used to generate hypotheses for future research about 
factors that may be associated with opioid diversion among PLWH. 
Despite these challenges, this study benefitted from several strengths. Most notably, 
we applied a unique methodology to estimate the prevalence of a behavior that is subject to 
strong social desirability bias, consequently rendering it difficult to study. The application 
of the crosswise method for indirect questioning allowed us to obtain an estimate for the 
prevalence of opioid diversion in our study population and provided a useful pilot study for 
future applications of this method to the study of opioid diversion. Another strength of this 
study is that our study sample came from an HIV clinic that is experienced in conducting 
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research and is composed of patients who complete ACASI surveys as part of their standard 
of care. This setting provided us with patients who are accustomed to participating in 
research studies and also research assistants who were available to assist with the 
implementation of the survey question and clarify the instructions if needed. This was an 
ideal setting to test an uncommon questioning technique. 
In this study, we found the estimated prevalence of opioid diversion using an 
indirect questioning method was nearly twice as high as the estimated prevalence obtained 
by directly asking the patients whether they have ever diverted opioids. The crosswise 
method for indirect questioning may be a useful technique for measuring the prevalence of 
opioid diversion while maintaining patients’ anonymity and reducing social desirability 
bias. Further, we confirmed that opioid diversion is a serious public health concern among 
PLWH. Not only do PLWH receive more opioid than their uninfected counterparts, but the 
excess of opioid prescriptions appears to be associated with a high prevalence of diversion. 
Careful prescribing behavior and more stringent interventions are needed to mitigate 
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Table 13: Characteristics of study sample 
N=1,158 patients who answered a screening question: “Has your doctor ever given you a 
prescription narcotic such as oxycontin, oxycodone, Percocet, fentanyl, tramadol, etc. to 
treat pain?” Patients who answered “Yes” to the screening question were included in the 
study sample. 
 Screening: ‘Yes’ 
N=541 




 N (%) N (%) N (%) 






















































































































































































































































































1HIV risk factors are not mutually exclusive  
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Table 14: Stratified prevalence estimates for opioid diversion by hypothesized risk 
factors 
Prevalence estimates for the indirect method are based on a probability of 0.235 for the 
non-sensitive question. 














30 to <40 








8.8 (0, 35.6) 
7.7 (0, 25.4) 
15.9 (0, 33.7) 







3.4 (0.1, 17.8) 
8.0 (3.0, 16.6) 
8.1 (3.3, 16.1) 








4.4 (0, 19.2) 





5.8 (2.2, 12.2) 








7.9 (0, 18.8) 





5.5 (2.8, 9.6) 
9.1 (2.5, 21.7) 










19.0 (3.6, 34.5) 







8.6 (4.0, 15.6) 
4.3 (1.6, 9.2) 







7.8 (0, 19.1) 





6.5 (3.4, 11.1) 
5.0 (1.0, 13.9) 







7.2 (0, 19.4) 





4.3 (1.7, 8.6) 








5.5 (0, 23.0) 





3.9 (0.8, 11.1) 
7.3 (3.8, 12.4) 
Depression 
None or minimal 





12.8 (0, 25.6) 





4.9 (2.4, 8.9) 
12.2 (4.1, 26.2) 
Anxiety 
None 





11.8 (0, 25.2) 





6.9 (3.2, 12.7) 








10.1 (0, 27.1) 





4.4 (1.2, 11.0) 








6.3 (0, 17.3) 





5.3 (2.6, 9.5) 









0 (0, 0.1) 





3.6 (1.0, 8.9) 








5.9 (0, 19.1) 





3.8 (1.3, 8.7) 
9.0 (4.2, 16.4) 







7.0 (0, 18.6) 





3.5 (1.3, 7.5) 
15.1 (6.7, 27.6) 





Table 15: Results from multivariate logistic regression models using crosswise 
technique 
Odds ratios for ever having diverted an opioid prescription; N=284 






1.24 (0.04, 39.01) 





0.69 (0.06, 7.48) 





2.76 (0.27, 27.89) 





















Supplementary Table 8: Summary of responses to opioid diversion questions 
Time period 1: October 24, 2016 through January 27, 2017 
Time period 2: January 28, 2017 through February 14, 2017 
Time period 3: February 15, 2017 through June 29, 2017 
 
 N (% of non-N/A responses) 
 Time Period 1 
N=470 
Time Period 2 
N=86 

































































































1Note: Between January 28, 2017 and February 14, 2017 everyone answered the indirect question, regardless of 
their response to the screening question (responses: 56 (74.7%) same, 19 (25.3%) different, 11 missing). The 




Supplementary Table 9 Estimated proportion of ‘yes’ responses to opioid diversion 
using Crosswise method of indirect questioning 
P(birthday)=0.235* P(birthday) = 0.242† P(birthday)=0.278‡ 
0.115 (SE 0.051) 0.104 (SE 0.052) 0.040 (SE 0.061) 
*Obtained from historical 1950 and 1955 CDC data and UN data for US births from 1969-2014 
†Calculated based on assumption of evenly distributed birthdays throughout the year  
‡Based on responses from 198 patients who directly answered the question about their mother’s birthday; 95% 








Appendix: Sample size considerations 
We calculated the sample size required to estimate the prevalence of opioid 
diversion in the JHHCC using indirect questioning by conservatively assuming a 25% 
probability of the non-sensitive question (CDC and UN data indicate a prevalence of 
23.5%). The required sample size to detect a non-zero prevalence with 80% power using a 
25% prevalent non-sensitive question and assuming a 15% true prevalence of opioid 
diversion is 218; therefore we aimed recruit 240 to ensure we can achieve the necessary 
power accounting for missing responses. Ulrich et al. explains the sample size calculation 
required for the crosswise method of indirect questioning17 .  
We calculated the sample size required for the direct questioning method assuming 
a reported prevalence of opioid diversion of 7%. Based on the same desired power (80%), 
Type I error (5%), and 10% non-response rate, we aimed to recruit 260 participants to 
directly answer whether they have ever diverted opioids. This would provide a sufficient 
sample size to detect a difference between the prevalence of opioid diversion as estimated 





Summary of findings 
Using Medicaid prescription claims data from 14 states across the United States, we 
found an increased prevalence of prescription analgesic use among PLWH compared to 
individuals without HIV since the start of the 21st century. All analgesic use increased 
sharply between 2001 and 2009, with a similar rate of increase regardless of HIV status. 
When we restricted the study sample to patients with diabetes and weighted the 
population by the inverse probability of having an HIV diagnosis, differences in the 
prevalence of analgesic use diminished, suggesting that the increased analgesic use among 
PLWH is primarily explained by differences in demographic and clinical characteristics. 
Overall, we found that PLWH did not receive fewer analgesics compared to patients 
without HIV with similar clinical and demographic characteristics (and, presumably, 
similar levels of pain), which is contrary to early reports of an under-treatment of pain 
among PLWH compared to their HIV-uninfected counterparts1–3, but consistent with recent 
literature suggesting an increase in opioid use among PLWH compared to individuals 
without HIV4,5.  
We found that progression to chronic opioid therapy (COT) among opioid-naïve 
individuals was relatively uncommon, with an overall incidence rate of approximately 9.6 
per 1,000 person-years. PLWH had a significantly higher incidence of COT, with an 
incidence rate of 29.1 per 1,000 person-years. In an unadjusted Cox regression model, 
PLWH had three times the hazard for COT compared to individuals without HIV, but the 
increased hazard became non-significant when we restricted the sample to a homogeneous 
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sample of patients with diabetes and adjusted for age, sex, state of residence, and relevant 
comorbidities. 
A detailed analysis of the trends in opioid use is an important first step in 
understanding the opioid epidemic among a vulnerable population, such as PLWH. 
Following our analysis of trends in opioid and non-opioid use over time and the association 
between HIV status and the incidence of COT, we examined the incidence of high-risk 
opioid use among a clinical cohort of PLWH from clinics in three urban US cities. We 
identified ‘high-risk’ opioid use by observing prescribing patterns, which is a surrogate 
marker for true opioid misuse; however, prescribing patterns have been used in prior 
literature to identify high-risk opioid use and these patterns have been validated against 
clinical outcomes such as overdose and opioid addiction6–16. We examined four prescribing 
patterns: high daily dosage, overlapping prescriptions, multiple prescribers, and early 
refills. 
In our sample of 1,794 incident opioid users living with HIV, approximately one 
third developed high-risk opioid use. The most common high-risk use behavior was 
multiple providers, with an incidence rate of 10.7 per 100 person-years. Early refills and 
overlapping prescriptions each had an incidence rate of approximately 9 per 100 person-
years, and high daily dosage was least common with an incidence rate of approximately 6 
per 100 person-years. Nearly half of the total cumulative incidence of high-risk use 
occurred within the first year after an opioid-naïve patient received an incident opioid 
prescription. 
Consequences of inappropriate opioid receipt are wide-ranging and include both 
intentional and unintentional behaviors, such as overdose, addiction and dependence. 
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Adverse events from opioid misuse can also occur among patients who did not receive an 
opioid prescription from a medical provider, but rather who received opioids illicitly from 
a family member, friend, or stranger. In fact, the majority of abused painkillers were 
obtained illegally through opioid diversion17. Because of its harmful effects and limited 
research, opioid diversion is an important behavior to study. 
We applied the crosswise method for indirect questioning18 to estimate the 
prevalence of opioid diversion in the Johns Hopkins HIV Clinical Cohort. Among a sample of 
284 PLWH, we estimated the prevalence of opioid diversion to be 11.5%, which was nearly 
twice as high as the prevalence we measured among 244 PLWH who directly answered 
whether they had ever diverted opioids (6.1%). We found that the indirect questioning 
method is an effective technique to apply to the study of opioid diversion, as patients tend 
to under-report this behavior. In a secondary analysis, we found that patients who had ever 
used cocaine were more likely to divert opioids; however, our small sample size precluded 
our ability to determine other factors that were significantly associated with opioid 
diversion. 
Implications and public health significance 
Prescription drug abuse has become a serious health problem in the United States in 
recent years19–24. The number of opioid prescriptions in circulation has increased 
dramatically24, causing adverse effects such as opioid abuse, addiction, and overdose. 
Reducing the number of opioid prescriptions in circulation is an effective way to minimize 
opioid misuse; an excess of opioid prescriptions can lead to diversion and overdose. 
However, refraining from prescribing opioid medications also has consequences, including 
the persistence of pain symptoms. There must be a delicate balance between over-
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prescription of opioids and under-treatment of chronic pain, particularly among high-risk 
populations such as PLWH who are at increased risk for both chronic pain and opioid 
misuse.   
Clearly elucidating the trends in opioid prescription patterns among PLWH and 
individuals without HIV was an important first step in studying the treatment of pain 
among PLWH. By using techniques such as weighting, restriction, and regression 
adjustment, we were able to compare PLWH to similar individuals without HIV to 
determine whether analgesic receipt and chronic opioid therapy differed by HIV status. 
Though differences in analgesic receipt by HIV status diminished after adjusting for clinical 
and demographic characteristics, which suggests similar treatment patterns by HIV status 
among patients with similar levels of pain, we did find a notably higher prevalence of 
analgesic use among PLWH in unadjusted trends. These results imply that PLWH have a 
greater need for analgesic prescriptions compared to individuals without HIV, emphasizing 
the importance of chronic pain management as a component of HIV treatment. 
Further, the similar increase we observed in both opioid and non-opioid analgesic 
prescriptions indicates a lack of evidence for a switch from non-opioid therapy to opioid 
therapy. Though we did not hypothesize a switch from one type of analgesic treatment to 
another, prior literature that describes overall increases in opioid prescriptions might 
imply a reduction in non-opioid analgesic therapies as patients turn towards opioid pain 
treatment. However, we found an increase in all analgesic therapy, suggesting that pain is 
either becoming a more prevalent condition, or patients are being treated for pain more 
regularly. With the development of guidelines to encourage appropriate opioid prescribing, 
 127 
we would hope to see a larger increase in non-opioid therapies compared to opioid 
medication in the future. 
The rise in opioid prescriptions is most concerning because it can lead to opioid 
misuse; it is important to study not only opioid prescribing but also high-risk opioid use. In 
our second study, we estimated the incidence of high-risk opioid use and described risk 
factors for high-risk opioid use using a large and comprehensive longitudinal clinical HIV 
cohort. We found that PLWH who receive opioid prescriptions often do so in patterns that 
are predictive of high-risk opioid use, with one third of incident opioid recipients meeting 
high-risk use criteria. This corresponds to a large proportion of all PLWH, as opioid use is 
common among PLWH. The results from our first two studies, in combination, confirm that 
PLWH are a particularly vulnerable population with respect to both opioid use and the 
potential for opioid misuse. 
Opioid prescribing should always be accompanied by a clear discussion of the 
proper use of opioid medication and the risks associated with opioid therapy. These 
conversations may be especially helpful to patients who are at highest risk for misuse. We 
found that high-risk opioid use was particularly common among patients with a history of 
injection drug use, non-Hispanic whites, patients aged 35-45 years, and patients who had 
not achieved HIV suppression. While all patients should undergo counseling when 
initiating opioid therapy, patients with these characteristics may benefit from additional 
counseling and careful monitoring.  
Our research on high-risk opioid use focused on PLWH. Nonetheless, some of our 
findings can apply not only to PLWH but to all high-risk populations and all patients whose 
opioid utilization behavior is tracked by prescription drug monitoring programs (PDMPs). 
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PDMPs help providers identify patients who receive opioids in patterns that are high-risk; 
however, they are often lacking in sensitivity and specificity and are consequently not often 
successful in identifying the most high-risk patients. We found correlation between the 
four high-risk use patterns we examined, though few patients met all criteria. Applying 
more sophisticated algorithms based on a combination of high-risk filling patterns could 
help improve the success of screening tools such as PDMPs. 
There is a notable lack of research on one particular form of opioid misuse: 
diversion. The increasing number of opioid prescriptions in circulation across the United 
States makes opioid diversion a serious concern, particularly among PLWH. More opioid 
prescriptions are dispensed to PLWH compared to patients without HIV; having greater 
access to opioid medication increases the likelihood of having excess drugs available to 
divert. Diverted opioids mean that some victims of opioid overdose have not received a 
prescription directly and therefore cannot be identified by healthcare providers as being 
at-risk for opioid overdose. Understanding the burden of opioid diversion is essential to 
fully recognizing the impact of the opioid epidemic in the United States. Identifying risk 
factors for opioid diversion can help health practitioners and policy makers create targeted 
interventions to minimize diversion. 
To our knowledge, the application of an indirect questioning technique to the study 
of opioid diversion has not been done previously. We used the crosswise method of 
indirect questioning to estimate the prevalence of opioid diversion in the Johns Hopkins 
HIV Clinical Cohort without the impact of social desirability bias and found a prevalence of 
diversion of nearly 12%. Though our study was conducted in a small and fairly 
homogeneous population of PLWH seeking care at one urban clinic in the mid-Atlantic 
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region, the success of our study has implications for future research. We found that indirect 
questioning methods may be a useful way to study opioid diversion. Obtaining consistent 
measures of opioid diversion can be used to determine the impact of interventions such as 
the implementation of prescription drug monitoring programs or strict prescribing 
guidelines on the reducing the prevalence of opioid diversion. 
Limitations and strengths 
Defining opioid and non-opioid analgesics 
 This research was subject to several challenges and limitations. A first challenge 
relates to the identification of opioid and non-opioid analgesics. We used a list of NDCs that 
was compiled by researchers in collaboration with clinical experts to define the analgesics 
included in our study. However, all analgesics were identified using prescription claims 
records alone, without knowledge of their clinical indication. With regards to the non-
opioid analgesics in particular, which included NSAIDs, anti-depressants, anticonvulsants, 
and muscle relaxants, the drugs are used for a variety of indications and are only 
occasionally used off-label to treat pain. In Chapter 2, it is possible that we attributed drugs 
to the treatment of pain when they were in fact being used for other indications. Also, some 
of the opioid analgesics included in both Chapters 2 and 3 could have been prescribed for 
the treatment of opioid addiction (i.e. buprenorphine); however, because all opioids are 
subject to misuse we chose a more inclusive definition for these analyses. 
Time period of data 
 A second limitation of Chapters 2 and 3 is that the data analyzed were collected 
nearly a decade ago. The opioid epidemic has become a serious public health concern in 
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recent years, leading to secular changes that might impact our results if our studies were 
repeated with more recent data. Nonetheless, understanding historic trends is valuable in 
its own right, as it puts recent trends into context and allows us to determine changes in 
the prevalence of analgesic prescriptions, the incidence of chronic opioid therapy, and the 
incidence of high-risk opioid use.  
Despite the timeframe of the data, we chose to use historic data for the Chapter 2 
analysis because of the immense value that the data provided. Specifically, Medicaid claims 
files provide information on a large subset of PLWH since Medicaid covers nearly 40% of 
insured PLWH27. Claims files served as the best data source for the analysis of trends in 
analgesic prescribing because they provide data on all prescriptions dispensed, regardless 
of the prescribing physician. Having existing access to these Medicaid files provided a 
significant advantage that allowed for a meaningful analysis. 
The data analyzed for Chapter 3 were collected between 2006-2010. As with 
Chapter 2, we chose to analyze these historic data because of the value they provided. The 
dataset for Chapter 3 was composed of both clinical cohort data from the HIV Research 
Network (HIVRN) and also comprehensive Medicaid pharmaceutical claims. Performing an 
individual-level linkage between the HIVRN and Medicaid is resource-intensive, and having 
such a rich data source available is rare. Therefore, despite the time period, these data 
provided us with a unique opportunity to analyze the incidence high-risk opioid use 
prescribing patterns and also examining demographic, clinical, and behavioral 
characteristics associated with the high-risk opioid use. 
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Challenges with primary data collection 
 We collected data for Chapter 4 by designing survey questions to add to an existing 
patient-reported outcomes survey. As is often the case with primary data collection, 
particularly when the questions involve a novel questioning technique, we faced challenges 
in the development and implementation of these questions. We performed a basic pilot test 
among a convenience sample of patients to ensure they understood the indirect 
questioning method and instructions. Nonetheless, most patients are unfamiliar with the 
technique and may have been confused by the questions.  
Additionally, we faced challenges in programming the question. In the first iteration 
of the indirect question, the two parts to the question (i.e. the non-sensitive question asking 
patients whether the patient’s mother’s birthday was in February, April, or November, and 
the sensitive question asking patients if they have ever diverted opioids) were 
programmed as separate questions. As such, we inadvertently collected data on patient’s 
mother’s birth month and direct responses to opioid diversion only. We were able to use 
the responses to the birthday question to validate our estimate for the prevalence of the 
non-sensitive question, but required additional time to complete data collection for the 
indirect question. Because the entire data collection period occurred over approximately a 
seven-month period, we do not expect that there were temporal trends that impacted our 
results. 
Innovation and contribution to the literature 
Though prior studies have described trends in opioid utilization and high-risk 
opioid use, this research contributed to the literature in several important respects. First, a 
unique feature of this research is that it focused exclusively on people living with HIV. 
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Much of the prior research on trends in opioid use has examined the entire US population, 
cancer patients, or patients with non-cancer chronic disease6,9,28–32. Little research has 
focused on analyzing trends among PLWH specifically.  
Another strength of this research is that we used longitudinal data, following 
cohorts of individuals over time both in Chapter 2 (using a closed cohort of Medicaid-
enrolled individuals) and in Chapter 3 (using a longitudinal clinical cohort). This allowed us 
to identify incident chronic opioid therapy and incident high-risk opioid use among opioid-
naïve individuals.  
Additionally, the research in Chapter 3 benefited from the innovative use of two 
distinct but complementary data sources: 1) Medicaid claims data, which provided 
comprehensive pharmaceutical information that is difficult to obtain, particularly in such a 
large quantity, using clinical or observational cohorts and 2) HIVRN clinical cohort data 
that provided additional information regarding socio-demographic, behavioral, and clinical 
information that we were unable to obtain from Medicaid databases. The ability to link 
records from the clinical cohorts to Medicaid allowed for a sophisticated and informative 
analysis that would not have been possible with either of the two data sources alone. 
Finally, the use of an indirect questioning method to estimate the prevalence of 
opioid diversion is novel to this field of study. Such techniques have been applied to illicit 
drug use in other populations, but to our knowledge this approach has not been used to 
study prescription opioid diversion among PLWH. The simultaneous application of the 
crosswise method of indirect questioning and the use of direct questioning allowed us to 
compare the prevalence of opioid diversion using two distinct methods and helped us to 
quantify the under-report of opioid diversion using direct questioning methods. 
 133 
Future directions 
Update analyses using data from recent years 
 This research could be strengthened by future studies that examine more recent 
trends in opioid and non-opioid analgesic utilization by HIV status. In Chapter 2, we 
analyzed prescription claims through 2009. Since then, changes in HIV treatment and 
acquisition as well as changes in opioid prescribing recommendations may have altered the 
associations we found in our analysis, either regarding the prevalence of opioid and non-
opioid analgesics or in the incidence of progression to COT by HIV status.  Extending the 
analysis we conducted in Chapter 2 to include analgesic prescription utilization since 2009 
would allow us to assess the impact of recent opioid prescribing guidelines and determine 
whether changes in opioid prescribing practices, including the recent stabilization and 
even decrease in some populations in the number opioid prescriptions across the United 
States24, differs by HIV status. 
 Similarly, further research is warranted to describe recent trends in the incidence of 
high-risk opioid use among PLWH. Widespread adoption of prescription drug monitoring 
programs by nearly all US states has impacted opioid prescribing behaviors, albeit to 
varying extents across states33, and consequently could impact the outcomes analyzed in 
Chapter 3. Because the rate of high-risk opioid use was high in our study population, there 
is an opportunity for significant improvement in opioid prescribing patterns among PLWH. 
It is currently not known whether, and to what extent, the recent focus on restricting 
opioid availability and minimizing inappropriate prescribing has impacted high-risk opioid 
use among PLWH. Analyzing trends in high-risk opioid use since 2010 would provide 
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evidence for the impact of recent prescribing guidelines and interventions on high-risk 
opioid use among high-risk populations such as PLWH. 
Validate and compare each high-risk prescribing behavior 
 In Chapter 3, we analyzed four distinct opioid prescribing patterns as a surrogate 
marker for high-risk opioid use. All four of these patterns have been used in research 
settings previously to describe high-risk use behaviors6–16, but to our knowledge they have 
not been directly compared to one another. To help determine the best method to identify 
high-risk opioid use through the analysis of prescription claims, it would be beneficial to 
conduct an analysis specifically comparing the four patterns, or various combinations of 
the patterns, to determine their association with clinical outcomes including addiction, 
dependence, overdose, diversion, and mortality. For example, it might be true that patients 
who meet criteria for two specific patterns are at highest risk for adverse outcomes. Future 
research that aims to identify the optimal application of prescription claims to detect high-
risk prescribing could provide guidance on identifying which patients are truly at highest 
risk for adverse outcomes. The results could be applied to existing prescription drug 
monitoring programs, improving their algorithms for detecting high-risk patients. Patients 
filling prescriptions in patterns that are most hazardous should be flagged, allowing 
providers the opportunity to reconsider prescribing the opioid or to provide additional 
counseling on the potential harms of the medication.  
Continue research on opioid diversion 
 The study of opioid diversion is still nascent. Though we know that the majority of 
overdoses occur from drugs that were obtained illicitly17, we do not have a clear 
understanding of the extent to which opioid diversion occurs. In Chapter 4, were conducted 
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a small study to determine whether the crosswise method of indirect questioning might be 
a feasible technique to study the prevalence of opioid diversion. We found that the 
prevalence of opioid diversion was nearly twice as high in our study population compared 
to using a direct questioning method, although the prevalence was still lower than the 
reported prevalence among European patients in opioid substitution treatment programs, 
which was up to 34%34,35. The field of research into opioid diversion would benefit from 
larger studies in more diverse study populations to estimate the prevalence of opioid 
diversion more broadly. Applying the indirect questioning technique on a larger scale 
would also allow for the estimation of stratified prevalence estimates and the analysis of 
risk factors associated with opioid diversion. Identifying sets of risk factors may allow for 
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